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ABSTRACT
MODELING OF FLEXIBLE DRUG-LIKE MOLECULES:
QSAR OF GBR 12909 ANALOG DAT/SERT SELECTIVITY
by
Kathleen Mary Gilbert

The dopamine reuptake inhibitor GBR 12909 and related dialkyl piperazine and
piperidine analogs have been studied as agonist substitution therapies acting on the
dopamine transporter (DAT) to treat cocaine addiction. Undesirable binding to the
serotonin transporter (SERT) can vary greatly depending on the specific substituents on
the molecule. This study uses Comparative Molecular Field Analysis (CoMFA) and
Comparative Molecular Similarity Indices (CoMSIA) techniques to determine a stable
and predictive model for DAT/SERT selectivity for a set of flexible GBR 12909 analogs.
Families of analogs were constructed from six pairs of naphthyl-substituted
piperazine and piperidine templates identified by hierarchical clustering as representative
conformers. Three-dimensional quantitative structure-activity relationship (3D-QSAR)
studies led to focused models that were stable to y-value scrambling. Test set correlation
validation led to one acceptable model (q 2 = 0.508, two components, r 2 = 0.685, average
residual = 0.00 for the training set, 0.22 for the extended test set). DAT/SERT
selectivities higher than that of the most active compound in the QSAR series were
predicted for nine novel compounds.
This is the first CoMFA/CoMSIA study of the highly flexible GBR 12909 class of
dopamine reuptake inhibitors. Previously, molecular modeling was based on more rigid
dopamine reuptake inhibitors, and often only on global energy minimum (GEM)
structures. Flexible molecules like GBR 12909 have multiple possible binding

conformations, distributed across the potential energy surface in key torsional angle
space, which can vary from the GEM by as much as 20 kcal/mol or more. The
significance of this study lies in the combining of a clustering technique for identifying
representative conformers from a set of low-energy (less than 20 kcal/mol from the
GEM) conformers with an extensive 3D-QSAR analysis based on each representative
conformer and analogs in a similar potential bioactive conformation.
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CHAPTER 1
INTRODUCTION

Cocaine addiction remains a significant problem around the world.' As with many
addictive drugs, the exact mechanism of the addiction has not been identified, although
focus has been on the interaction of cocaine with various neurotransmitter systems. 2 The
"dopamine hypothesis" 3 ' 4 implicates the dopamine transporter (DAT) in cocaine abuse
and addiction. Structure-activity relationship (SAR) studies for several classes of
dopamine (DA) reuptake inhibitors (shown in Figure 1.1) have been reviewed 2'58 and
document the search for a selective DA reuptake inhibitor that could be used in an
agonist-substitution therapy treatment for cocaine addiction.
GBR 12909 (1) is a promising drug
candidate, having demonstrated a decrease
in cocaine-maintained responding without
affecting food-maintained responding in
behavioral studies of rhesus monkeys 9 and
having passed Phase I clinical trials. 1 In addition, prior use of cocaine caused crosssensitization for several DA reuptake inhibitors, but not for 1. 11 Compound 1, also
known as vanoxerine (CAS No. 67469-78-7), and related dialkyl piperazines and
piperidines have also been shown to bind selectively to the DAT cocaine binding site and
cause minimal DA reuptake inhibition, without causing other of cocaine's deleterious
side effects. SAR studies of hundreds of analogs of 1, based on the scaffold shown in
Figure 1.2, have been summarized in a recent review.

1

12

Most DA reuptake inhibitors

2

Figure 1.1 Cocaine and representatives of four classes of dopamine reuptake inhibitors.

Figure 1.2 Template for GBR 12909 analogs. X can be either H or F, Y is a nitrogen for
piperazine analogs, and a carbon for piperidine analogs. The R group is a naphthalene
for analog 2 and analog 3, and can be a variety of aromatic or non-aromatic substituents.
n and m are usually equal to 1; however, n=1 and m=0 for five-membered rings and n=1
and m=2 for seven-membered rings.

have common structural features, such as an aromatic ring located near a quaternary
nitrogen (as seen for example in the relationship between the center ring nitrogen and Aside in Figure 1.2) that appear to be necessary for DAT binding. However, photoaffinity
labeling studies indicate that 1-like and tropane-like compounds (such as cocaine) may
bind to different regions in the DAT 13 or bind in a somewhat different manner. 14 ' 15
Compared to a 2-benzhydryloxyethyl substituent, presence of a 2-[bis-(4fluorophenyOmethoxy]ethyl- substituent (identified as the B-side in Figure 1.2) usually
results in better DAT binding affinity, but in some cases decreased DAT/serotonin
transporter (SERT) selectivity, although neither effect was significant compared to
modifications of the A-side. 16-2° Most SAR studies have focused on either the piperazine
or piperidine analogs of 1, although the trend has been towards piperidines because 1
analog piperazines could bind to the "piperazine acceptor site" found in the brain and
liver, identified as a cytochrome P450. 21 In order to focus on the activity of piperazine
and piperidines, the present three-dimensional quantitative structure-activity relationship

4

In the absence of knowledge of the three-dimensional structure of the DAT,
ligand-based 3D-QSAR techniques such as Comparative Molecular Field Analysis
(C0MFA)22 and Comparative Molecular Similarity Indices (CoMSIA) 23 may be useful in
identifying molecular features that improve activity. However, these techniques require
the use of a template conformer, i.e., a putative bioactive conformer, upon which each
3D-QSAR model is based. For rigid molecules that can adopt only a limited number of
conformers, selection of the template conformer is relatively straightforward. To date,
molecular modeling studies have focused on fairly rigid classes of DA reuptake
inhibitors, such as tropanes, 2436 piperidine-based cocaine analogs, 37 benztropine, 36 38 39
'

'

BTCP,40° bupropion,41 mazindol,42 methylphenidate, 43 ' 44 novel piperadinols, 45 and more
rigid bicyclic 1 analogs, 46 some examples of which are shown in Figure 1.1.
Although there is considerable evidence that many ligands do not bind to proteins
in their vacuum phase global energy minimum (GEM) conformation, 4752 many
pharmacophore models of DA reuptake inhibitors have been based on the GEM structure

5
of the ligand, or on a few structures very close in energy to the GEM.

28 ' 42 ' 53

Other work

has shown the necessity of considering conformations other than the GEM in
pharmacophore modeling, especially when modeling very flexible molecules. 5459 For
example, the Venanzi group's conformational analysis of the DA reuptake inhibitor
methylphenidate 60° identified several conformations within a few kcal/mol of the GEM
structure that are potential bioactive conformers. Subsequent CoMFA analysis and
comparison to a rigid methylphenidate analog with the same DAT binding affinity as
methyiphenidate supported the idea that the bioactive conformation need not be the GEM
conformer. 44
Since large, flexible molecules such as the 1 analogs can take on a continuum of
closely-related conformations, they present a challenge to the application of 3D-QSAR
techniques. The significance of this study lies in the combining of a clustering technique
for identifying representative conformers from a set of low-energy (less than 20 kcal/mol
from the GEM) conformers with an extensive 3D-QSAR analysis based on each
representative conformer and analogs in a similar potential bioactive conformation.
Conformational analysis of 2 and 3 was carried out,6 with hierarchical clustering used to
select representative conformers to use as templates in 3D-QSAR studies. 62 These
templates were chosen to be representative of the regions of three-dimensional space
occupied by the analogs. In this research, CoMFA and CoMSIA techniques were used to
analyze conformational families of forty-five 1 analogs (23 analogs of 2 and 22 analogs
of 3) which differ only in their A-side substituents. Six conformational families were
constructed from six pairs of template conformers identified by hierarchical clustering as
representative molecular conformations of 2 and 3.

6
CoMFA and CoMSIA studies were performed on the selected molecules.
CoMFA studies encompassed a range of electrostatic and steric cutoffs for each
conformational family. CoMSIA studies were done for each of the basic field options:
hydrogen donor and acceptor, hydrophobic, and steric and electrostatic. The CoMSIA
studies were included to give a higher potential for computing significant models because
different field types are available as compared to CoMFA. 23 ' 63 Six sets of
CoMFA/CoMSIA studies were carried out, one for each conformational family. Partial
least squares (PLS) analysis was performed on the CoMFA and CoMSIA results, with the
q2 (predictivity) and r2 (goodness-of-fit) values and associated statistics being calculated.
PLS Region Focusing was applied to the best CoMFA or CoMSIA results for each
preliminary study. Internal validation (y-value scrambling) and external validation (test
set correlation validation) methods were used to determine the most predictive and stable
model. The present work is the first CoMFA and CoMSIA study of multiple potential
bioactive conformations of highly flexible analogs of 1.

CHAPTER 2
BACKGROUND

2.1 Overview and Objectives

Currently, there are no medications that can be prescribed in the U.S. to treat cocaine
addiction, although cocaine addiction remains a significant problem. As for many
addictive drugs, the exact mechanism of cocaine addiction has not been identified. This
work is based on one significant hypothesis of addiction, the "dopamine hypothesis", 3 '4
which applies to cocaine along with other addictive drugs and certain addictive
behaviors. According to this hypothesis, cocaine's effect on the DAT is implicated in the
addictive effects of cocaine. The DAT releases DA into the synaptic junction of certain
nerve cells and reuptakes DA from the synaptic junction. Among its modes of action,
cocaine binds to the DAT, inhibiting the reuptake of DA (Figure 2.1). A compound that
binds to the cocaine binding site on the DAT, causing some DA reuptake inhibition, but
having a minimal effect other neurotransmitter systems, could block the negative actions
of cocaine on the body. These selective DA reuptake inhibitors are being explored as a
potential treatment for cocaine addiction.
Mutagenesis studies have been performed on the DAT to elucidate the effects of
cocaine at the DAT, 64 ' 65 but the three-dimensional structure of the DAT is not known. 5
Therefore, ligand-based 3D-QSAR techniques such as CoMFA 22 and CoMSIA 23 may be
useful to help identify molecular features that improve DAT binding or DAT/SERT
selectivity. The DAT is a Na + Cl - ion-dependent transporter, and the effect of Nay +
concentration on DAT ligand binding has been studied. 66 Key residues involved in

7

Figure 2.1 DAT at the synaptic junction. The influence of cocaine binding is shown.
From National Institutes of Health (NIH) Publication Number 99-4342 Cocaine Abuse
and Addiction, May 1999.

cocaine analog binding have been identified, including tryptophans and aspartates,
although it appears that different residues affect cocaine-like and dissimilar DA reuptake
inhibitors. 65 Selectivity of DA reuptake inhibitors is also an issue, especially relative to
other Na+ Cl - ion-dependent transporters like the SERI, binding to the SERT and other
transporters may cause undesirable side effects and diminish the relative effect of a dose
of a DA reuptake inhibitor, part of the dose binding other transporters instead of only the
DAT. The majority of the compounds have an acceptable low nanomolar DAT binding
Kid , with a wider range of SERT binding Kid's; therefore, the DAT/SERT selectivity of the
compounds was modeled.

9

Although CoMFA studies have been carried out on other classes of DA reuptake
inhibitors, such as tropanes, 24 ' 26 mazindols, 42 and benztropines, 36 '38 no CoMFA or
CoMSIA studies have been done on 1 analogs. A chemometric QSAR study was done on
1 analogs, but used only a single minimized structure for each analog. 53 The study used

GRID 67 independent descriptors (GRIND), 68 a method that takes the molecular
interaction fields (for example, hydrophobic or hydrogen-bond donor) calculated by
GRID to create several variables that represent regions where energetically favorable
interactions can occur, to model DAT/SERT selectivity and found predictive models. In
contrast, the present study looks at multiple low energy conformations, and no
assumption is made that the GEM is the conformation a molecule must achieve (the
bioactive conformation) in order to bind to a target. This project is the first detailed
CoMFA and CoMSIA study on multiple potential bioactive conformers of 1 analogs.
The objectives of this study are:
•

To use conformational analysis and clustering methods to identify low-energy
conformations that represent the wide range of conformations attainable by
the piperazine 2 and the piperidine 3

•

To use CoMFA and CoMSIA 3D-QSAR techniques to identify a model for
DAT/SERT selectivity

•

To provide the modeling results as a contribution to the iterative cycle of
synthesis, pharmacological testing, and modeling with a goal of development
of a treatment for cocaine abuse

2.2

Cocaine Addiction and the Dopamine Hypothesis

DA reuptake inhibitors target the "cocaine binding site" on the DAT. Cocaine's
addictive properties are thought to be at least in part due to an increase in synaptic DA
achieved by reuptake inhibition of DA at the DAT. The "dopamine hypothesis"3'4
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implicates cocaine's inhibition of DA reuptake as the reason for cocaine addiction.
However, it is noted that cocaine and methyiphenidate (the active ingredient in the
common attention-deficit/hyperactivity disorder medication Ritalin ®) both bind to the
DAT and cause DA reuptake inhibition, yet methyiphenidate is not addictive like cocaine
and does not cause the same level of negative side effects. 69 Using methyiphenidate or 1
analogs to treat cocaine abuse is dependent upon the complex nature of cocaine's effect
on the body; the methyiphenidate and 1 analogs are dissimilar enough from cocaine to
not have the multi-target binding profile of cocaine. The "reward response" to cocaine
use mediated by the DAT is mimicked by methyiphenidate analogs and 1 analogs,
without some of the negative side effects such as addiction." Use of 1 for agonist
substitution therapy has been proposed, because 1 binds to the DAT, but does not
substantially increase extracellular DA. 7
Chief attributes of the best candidates for treating cocaine addiction via agonist
substitution are expected to be:
•

high binding affinity at the "cocaine binding site" on the DAT,

•

partial (i.e., minimal) DA reuptake inhibition,

•

high selectivity for the DAT versus the SERT, and

•

desirable kinetics of slow on-rate and slow off-rate when binding to the DAT.

The first three attributes can be predicted from models using the following activities:
•

DAT binding affinity, measured by the displacement of radiolabeled cocaine
analog [ 125I]RTI-55 5 from the DAT,

•

DA reuptake inhibition, measured by the decrease of synaptic DA in response
to binding, and
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• SERT binding affinity, measured by the displacement of radiolabeled cocaine
analog [ 125I]RTI-55 from the SERT.

Binding affinities are equal to Kid, calculated from: 72

where the Kid is the inhibition constant (the dissociation constant of the test compound),
1C50 is the concentration of the radiolabeled cocaine analog [ 1251]RTI-55 that is displaced
from the DAT or SERT, S is the concentration of free [ 1251]RTI-55, and Kid is the binding
affinity constant of [ 1251]RTI-55, calculated from saturation binding experiments. It can
be seen that if the amount of free radioligand is small compared to the binding affinity of
the radioligand, the Kid is nearly identical to the 1C50 value. This is the case for all of the
experimental data provided for this study by Richard Rothman of the National Institutes
of Health (N1H).
DAT/SERT selectivity is calculated from the following equation:
DAT/SERT selectivity = log[ (DAT binding activity) / (SERT binding activity) ] (2.2)
where:
DAT binding activity = 1 / (DAT binding affinity Kid)

(2.3)

SERT binding activity = 1 / (SERT binding affinity IQ

(2.4)

therefore:
DAT/SERT selectivity = log[ (SERT binding affinity IQ / (DAT binding affinity Kid)
(2.5)
DAT/SERT selectivity is modeled in this study because selectivity for the DAT over the
SERT increases specificity for the DAT and decreases potential side effects from SERT
binding. Most of the DAT binding affinities of the analogs studied are in an acceptable

12
low nanomolar range of DAT binding affinity. The direct DAT/SERT selectivity was
used instead of scaling against cocaine's DAT/SERT selectivity because experimental
values for cocaine's DAT/SERT selectivity are near 1. 7 DAT/SERT selectivity has been
a target for the N1H and other researchers as well. 14 20 46 53 73 74
'

'

'

'

'

2.3 Classes of Dopamine Reuptake Inhibitors
There are five major classes of DA reuptake inhibitors being studied for their cocaineblocking properties: tropanes, benztropines, mazindols, methylphenidates, and 1 analogs.
The structure of cocaine and typical structures of the first four classes are shown in
Figure 1.1. A recent review of DAT binding compounds has been published and a
slightly older, but extremely comprehensive review of DAT binding compounds oriented
towards treatment of cocaine abuse is available

2.3.1 Tropanes and Other Cocaine-Like Dopamine Reuptake Inhibitors
Tropanes were developed based on the bicyclic cocaine backbone. Like cocaine, they
have the bicyclic backbone with a quaternary nitrogen and acetyl side chain, but in
position 3, various substituents replace the benzoyl moiety. 75 Three tropanes are
commonly used for binding studies; each has a phenyl substituent instead of the benzoyl
substituent. WIN35065-2 (C1T) 78 has a phenyl substituent, W1N35428 (CFT) 76 ' 77 has a
4-fluorophenyl substituent, and RTI-55 (C1T) 78 has a 4-iodophenyl substituent. 79
Cocaine and related tropanes bind to other proteins, especially the SERT and the
norepinephrine transporters, and thus may cause side effects or dilution of activity. The
tropanes CPT, CFT, and C1T have been used extensively for radiolabeling DAT and
SERT; this QSAR study is based on [ 125 1]RTI-55-labeled DAT and SERT, using
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techniques to isolate one transporter or the other. 80° Many other tropane compounds that
act on the DAT have been synthesized and analyzed. 24-2729
" 3077
" 79

81-123
,

Piperidine-based cocaine analogs have also been developed, with a piperidine ring
in place of the tropane ring. These compounds have shown varying levels of
activity.79,124 A recent QSAR study of piperidine-based cocaine analogs identified two
potential binding modes with different 3a- substituent binding characteristics. 37

2.3.2 Benztropine Dopamine Reuptake Inhibitors
Benztropines are similar to cocaine and other tropanes, but lack the acetyl side chain and
have a diphenyl methoxy or similar substituent in position 3, which makes them more
similar to 1 analogs than any other DAT binding

ClaSS. 36 , 38 , 39 ' 125-133

Benztropine is

currently used to treat Parkinson's disease, as well as drug-induced Parkinsonian
symptoms.

2.3.3 Mazindol Dopamine Reuptake Inhibitors
Mazindol has been used as an appetite-suppressant with actions similar to amphetamine.
Although mazindol analogs contain a quaternary nitrogen and aromatic moieties, the
resemblance to cocaine, tropanes, and benztropines ends there. Mazindol itself consists
of three fused rings, with a phenyl ring attached to the center ring. There has been
considerable SAR work on the series, including accompanying 3D-QSAR studies in
some cases. 42,134-142
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2.3.4 Methyiphenidate Dopamine Reuptake Inhibitors
Methylphenidate also has a different structure than cocaine, but includes the quaternary
nitrogen and aromatic substituent present in the other DAT binding families. 43
Methylphenidate is familiar as the active ingredient in Ritaline®, although that
prescription drug is a mixture of the active 2R, 2'R (D-threo) and the much less active 2S,
2'S (L-threo) enantiomers. 143,144 SAR studies and analyses have been completed on
methyiphenidate analogs,l45-153 including pyran analogs that are among the first DAT
binders developed to have high affinity for the DAT without containing a nitrogen
atom. 154 The Venanzi group has completed detailed conformational analysis of
methylphenidate 60° and CoMFA studies on phenyl-substituted methylphenidates. ,156
These CoMFA studies will be published along with comparisons to novel rigid
methylphenidate60 The conformational analysis and CoMFA work on methyiphenidate
is summarized below.
2.3.4.1 Conformational Analysis of Methylphenidate. To identify possible bioactive
conformers, the Venanzi group performed detailed conformational analysis of
methylphenidate and related rigid methylphenidates using multiple molecular modeling
methods.60° Hartree-Fock 6-31G*
theory (B3 LYP/6-3 1 G*),159

158

basis set calculations as well as density functional

Am1ism5.4,160-162

and Tripos force field l63 calculations

were performed using the Gaussian 98 164 (available from Gaussian, Inc., Wallingford,
CT), Spartan (available from Wavefunction, Inc., Irvine, CA), and SYBYL ® (available
from Tripos, Inc., St. Louis, MO) software. These techniques were used to explore the
potential energy surface (PES) of neutral and protonated methyiphenidate, as well as that
of several rigid methylphenidate invertamers. In addition, methods were compared to
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determine whether the less computationally-intensive force field molecular mechanics
method gave similar results to molecular orbital methods. All methods gave local
minima in approximately the same regions of torsional angle space. The Tripos force
field molecular mechanics random search found at least one conformation in each local
minimum area of the methyiphenidate PES, thus validating the utility of this technique
compared to more computationally-intensive ab initio methods.
2.3.4.2 Methyiphenidate CoMFA Studies. CoMFA studies were performed on
representative templates of neutral 155 and protonated 156 phenyl-substituted
methylphenidate analogs The DAT binding affinities for methyiphenidate and 29
analogs were modeled using CoMFA at a comprehensive set of steric cutoff/electrostatic
cutoff/column filtering (a) combinations. Template conformers of the conformational
families with the best CoMFA results were compared to the conformations of rigid
methyiphenidate analogs that have the same binding affinity for the DAT, leading to
three potential bioactive conformations whose results matched well for both neutral and
protonated studies.

2.3.5 GBR 12909 Dopamine Reuptake Inhibitors
2.3.5.1 Discovery of GBR 12909 and Applications. Compound 1 is a 1,4-disubstituted
piperazine that was first synthesized in the 1970's at Gist-Brocades N.V., a Netherlandsbased food product and biotechnology company. It was initially investigated in Europe
as an antidepressant, but was targeted as a potential treatment for cocaine abuse in the
late 1980's. 165 Researchers at the N1H have studied 1 and related compounds for their
potential use to modulate cocaine addiction.
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Towards this end, over 300 related compounds were synthesized and their DAT
and SERT binding affinities tested by the Rice and Rothman groups at N1H,
18,20,166,167

12,l4,16-

exploring many aspects of the complex structure of 1. The data has been

provided to the Venanzi group for QSAR and pharmacophore modeling. The present
study is the first step in the computational analysis of these compounds. Forty-five
analogs of 1 that are based on the structures of 2 and 3 were selected for this study
because they have fewer rotatable bonds than 1 and thus are easier to model. Three
additional compounds, including 1 and two similarly flexible 1 analogs, were added as
additional test set compounds. The range of DAT/SERT selectivities (equal to the
logarithm of the ratio of DAT binding affinity to SERT binding affinity) covers more
than three log units, a recommended range for QSAR studies. 168
2.3.5.2 Structure-Activity Relationships of GBR 12909 Analogs. The three major
areas of 1, noted above in Figure 1.2, have been subjected to many changes. 12
Elimination of the B-side resulted in extremely poor DAT binding (K = 30,000 nM for
both DA uptake and DAT binding). Addition of single atom para substituents to both Bside phenyl rings has been well tolerated. Adding substituents to only one phenyl ring
has been studied, with position 3' substitutions being better tolerated than 4'substitutions. 169 Selectivity studies have generally not been performed for B-side
structures other than those with para hydrogen and para fluorine phenyl ring
substituents.
The center ring has been modified in various ways, including conversion to a
tropane-like bicyclic ring, 17° and addition or removal of a carbon atom. Changing the
piperazine to a seven-membered diazepane ring resulted in no detectable DAT binding by
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measuring [ 125I]RTI-55 displacement: Other variations on the center ring include a fivemembered 1,2-substituted azolidine ring with a nitrogen in the second position from the
center ring: This compound showed approximately one-fifth the DAT binding affinity of
1: DAT binding affinity was also poor when the center ring was changed to an acyclic

N,N-dimethyl-1,2-diamine ethane; no displacement of [ 125I]RTI-55 from the DAT was
detected at all: Removal of the A-side resulted in no detectable DAT binding for
[ 125I]RTI-55 studies, and poor DA uptake (Kid = 71 nM): Methyl substituents at the 2- and
5- positions have been added, improving DAT activity but these compounds performed
poorly in studies on laboratory animals: A similar trend was seen when adding a twocarbon bridge to compound 1 across the A-side nitrogen: Other researchers have
explored center rings with oxygen instead of nitrogen 171 and constrained bicyclics as
well:46 The modification from a piperazine ring to a piperidine ring has resulted in better
DAT binding affinity and DAT/SERT selectivity; 74 ' 172 for this reason, both piperazine
and piperidine 1 analogs are included in this study:
A-side substitutions have been numerous: The original 3-phenylpropyl
substituent has been modified to include a double bond (slightly improved DAT binding)
or a bisphenyl substituent (better DAT binding in bench experiments but performs poorly
in animal models): Removal of flexible bonds from the A-side has been a focus of
studies; substituents include methylnaphthyl substituents and other double ring systems
(for example, thiophene, benzofuran, and quinoline): Different attachments of the double
ring systems have been explored: Adamantyl and ethynylbenzyl substituents have also
been used as A-side substituents: Work on piperidine analogs has resulted in many parasubstituted phenyl rings with high DAT binding affinities, with the cyan and
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trifluoromethyl substituents showing especially good DAT binding: These multiple
studies have shown that the SAR characteristics of 1 are complex indeed, with hundreds
of data points available on as many permutations of the structure: This study focuses on
a sample (forty-five 1 analogs) of the hundreds of compounds studied, to highlight the
effect of A-side substitution on the DAT/SERT selectivity of 1 analogs:

2.3.6 Shared Pharmacophore Elements of Dopamine Reuptake Inhibitors
As noted, all of the above classes of DA reuptake inhibitors share at least two
pharmacophore elements: a quaternary nitrogen and an aromatic ring. Figure 1:1 shows
that the torsional angles T 1 and T2 in methyiphenidate determine the relative orientation
of these two pharmacophore elements: Figure 1:2 shows that Al and A2 provide a
similar relationship for 2 and 3:

The Venanzi group has performed conformational

analysis of methyiphenidate, 2, and 3 in order to investigate whether these two classes of
DA reuptake inhibitors might share a common pharmacophore: Figure 2.2 shows
conformational energy minima for methyiphenidate, plotted in (Ti, T2) torsional angle
space, and 2 and 3, plotted in their counterpart (Al, A2) conformational space:
Comparison of the local minima of methyiphenidate to those of 2 and 3 indicates that
these two very different classes of DA reuptake inhibitor appear to attain a similar
orientation of their quaternary nitrogen and aromatic substituents. The similarity of the
T1 and T2 torsional angles in methyiphenidate to the Al and A2 torsional angles in 2 and
3, and the fact that these compounds all displace [ 1251]RTI-55 bound to the DAT supports
the hypothesis that the pharmacophores for the two classes of partial DA reuptake
inhibitors are similar:
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Figure 2.2 Local conformational minima for protonated methyiphenidate and GBR
12909 analogs. Ti and T2 values for protonated methylphenidate (black circles), and Al
and A2 values for analog 2 (red triangles), and analog 3 (blue diamonds): Results for
protonated methylphenidate are shown with both positive and negative T2 values because
of the symmetry of the phenyl ring: Local minima are SYBYL random search
conformations found within 20 kcal/mol of the GEM for each molecule:
2.4 Synthesis and Pharmacology
Synthetic work was carried out by Dr: Kenner C. Rice's group at the National Institute
for Diabetes and Disorders of the Kidneys, part of N1H: Binding and uptake experiments
were conducted by Dr: Richard B: Rothman's laboratory at the National Institute on Drug
Abuse at Nat l2,l4,16-20,71,73,80,166,167,170,173-193 Four experimental results are of interest to

this project: DAT binding, DA uptake, SERT binding, and serotonin (SER) uptake:
DAT binding was measured by loading synaptosomes with radiolabeled [ 125I]RTI-55 and
measuring the amount of radiolabel remaining after incubation with a test compound.
DA uptake inhibition was measured by determining the decrease in the amount of DA in
the synaptosomes after incubation with a test compound: SERT binding and SER uptake
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inhibition were measured in a similar way, using blocking techniques to isolate SERT
binding from DAT binding. 80

2.5 Molecular Modeling and Conformational Analysis
With the advent of the computer in the 1980's, computerized molecular modeling began
to progress rapidly as well, being previously relegated to large institutions with extensive
computing resources and costing inordinate amounts of computational time:
Computerized molecular modeling is based on a set of approximations of the interactions
of atoms and how they form molecules: Molecular mechanics uses empirical force field
parameters to define the shape, potentials, and interactions of atoms in a given molecule.
The molecular modeling package SYBYL uses the Tripos force field 163 to calculate the
attributes of molecules, including atom locations and relationships: Classical mechanical
forms, such as springs with differing elasticity constants, are used to represent different
atoms: Force field parameters are derived by fitting equations to experimental results:
Molecular mechanics methods use a series of equations to derive the locations of
atoms in a molecular structure. All molecular mechanics methods use a total energy
equation calculated as a result of different intra- and inter-atomic forces in the molecule:
The Tripos force field uses the following equation to calculate the total energy of a
molecule:

where: E st is the energy of a bond stretched or compressed from its natural bond length,
Abend is the energy of bending bond angles from their natural values,
E 001, is the energy of bending planar atoms out of the plane,
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Etors is

the energy due to twisting (torsion) about bonds, and
wiEsthenvrgyduoa Wlsfrcebtwno-dams.

E e l, is the energy due to electrostatic interactions, and is optional depending on the user's
selection. Absolute values of the energies found when using empirical molecular
mechanics calculations are meaningless. Relative energies for different conformations of
the same molecule, and conformational energy differences between different molecules
(that is, relative to their own GEM) do have meaning. These techniques lend themselves
to mathematical comparison of molecules in order to predict relative activities of the
compounds.
Conformational analysis of molecules with many rotatable bonds is
computationally intensive. A full grid search, by systematically changing all eight key
torsional angles and subsequent minimization of each resulting structure, would produce
over 400 million conformations for 30° increments of the torsional angles. A wider grid
spacing of 60° for each torsional angle would produce almost 1.7 million conformations.
For this reason, the random search method l94 was selected as an appropriate way to
sample the energy minima on the PES of these flexible molecules. SYBYL's
implementation of random search uses random variation of selected torsional angles and
minimization of the randomized structures with the Tripos force field. An
interconformational root mean square deviation (RMSD) cutoff is used to remove
duplicate conformers. The RMSD is calculated from the atom locations of the new
conformer and each existing conformer; a new conformer that is within the RMSD cutoff
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of any existing conformer is discarded. The exhaustiveness of a random search can be
estimated by the following equation: 194
Probability of finding all conformers = 1 - (0.5) n(2.7)
where n = the minimum number of times any conformer is found. Finding almost all
low-energy conformations is probable with small and less flexible molecules, within a
reasonable search time. However, for molecules like 1, 2, and 3, it is probable that not all
energy minima will be found, or that conformations must be limited by a high RMSD
between atoms in similar conformations (equivalent to a wider grid spacing for a grid
search). Random search combined with clustering of the conformations can be a
computationally efficient method to facilitate representation of all potential low-energy
binding conformations, instead of using a high interconformational RMSD cutoff value
which may arbitrarily remove important conformations based on search order.

2.6 Clustering

CoMFA results are notoriously dependent upon the conformer used as the template
structure. Highly flexible molecules have a continuum of conformers covering the many
changes in their torsional angles. In the present work, a series of CoMFA and CoMS1A
calculations are carried out on different template structures, which are representative
conformers identified using hierarchical clustering. Clustering is a method that takes
many data points (or sets of data points) and finds groupings based on the similarities of
one or more features of the data set. Items that share a cluster are assumed to be similar;
items that are not in the same cluster are assumed to be dissimilar. Clustering can be
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applied to many systems, but chemists have found it especially useful to reduce large sets
of conformations to a few representative conformers. 195

2.6.1 Types of Clustering

Clustering techniques can range from visual inspection to complex computational
techniques. All clustering techniques involve a feature set selected either manually by
the user, or automatically by the computer program. For molecules, a feature set might
consist of atom locations, distances between atoms, angles, or torsional angles. Visual
inspection can be performed on graphs created by selection of two features, one for each
axis. Automatic and exhaustive searching of possible feature sets (realizing that a feature
set can have any combination of features, from one to the maximum in the set) is not
available for general chemical systems. However, clustering based on root-mean-square
deviations (RMSDs) of all key atoms in a data set, such as carbon backbones in proteins,
has been used for very large data sets, such as those in the Protein Data Bank.

196

Two basic types of clustering methods exist: hierarchical and non-hierarchical.
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Hierarchical methods can be perceived as "joining" clusters if proceeding from individual
data points to agglomerated clusters, or "splitting", if clusters are separated from one
cluster comprising the entire data set. Many hierarchical clustering algorithms join
clusters, where data points are joined into clusters by the highest similarity (for example,
the lowest RMSD), going from N clusters, where N = number of data points, to one
cluster. Identification of the optimal clustering level can be performed automatically or
manually to meet the specifications of the user, such as number of clusters desired or size
of average cluster. A further division of hierarchical clustering methods is between
"single-chain" linking and "multiple-chain" linking. Single-chain linking hierarchical
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clustering programs, such as XCluster, 198 successively look for pairs of data points which
have the highest similarity in terms of the feature set. The relationship between a single
data point and the other members of the cluster it is joining, other than its nearest
neighbor in the cluster, is immaterial, although this nearest neighbor was obviously found
earlier to link to another member of the cluster. Multiple-link clustering can drastically
increase computational time, as each member in a cluster needs to be compared to a
potential new member. A compromise is to compare the feature set of a potential new
member to the centroid of the feature set of the existing cluster, the centroid being made
up of the average value of each feature.
Non-hierarchical clustering methods generally require selection of the desired
number of clusters as an input, in addition to identifying a feature set where necessary.
Although the computational time is decreased compared to hierarchical clustering
because the number of clusters is usually set low (less than 10), the possibility of partial
membership in a cluster (e.g., fuzzy clustering) increases computational time. k-means
clustering is non-hierarchica1, 199 finding the n most dissimilar data points, where n equals
the target number of clusters, then adding data points to each cluster by similarity to this
initial set.
Clustering data points is not usually an end in itself in conformational analysis of
a single molecule; rather, finding the centroid or data point nearest the centroid in each
cluster is the goal. Versatile clustering programs allow identification of data points
representing clusters that are inside (a member of) or outside (not an actual member) of
the data set, based on average values of features or other criteria.
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2.6.2 Hierarchical Clustering as Implemented in XCluster
As noted above, XCluster is a single-link hierarchical clustering method which was
designed specifically for clustering of molecular conformations. As such, issues such as
circularity of torsional angle data and molecular symmetry are handled automatically
with some user options available. Circularity of torsional angle data addresses the fact
that torsional angles are polar coordinates, and need to be treated differently than scalar
values. For scalar values, the shortest distance between two points is the simple
difference of their values. The scalar distance between torsional angles may or may not
be the correct shortest distance, because 0° = 360° = 720° etc. all represent the same
torsional angle. For example, the shortest distance between 350° and 5° torsional angles
is 15° degrees, not the simple difference 345°. Symmetry issues include not considering
equivalent carbons, such as those in the ortho positions on symmetrical phenyl rings, as
different atoms.
Based on the selected feature set/alignment option, XCluster performs clustering
by first calculating an intermolecular distance matrix of a set of superimposed molecules.
For feature sets consisting of atoms only, XCluster allows the user to select a new
superposition, or to use the molecular database's existing superposition. In the case of
atom superpositions, each interconformational distance is a RMSD average between
locations of the atoms in the feature set. Superpositions are not applicable to torsional
angle-based clusterings, since in that case, the distances are calculated based on torsional
angle values, as opposed to atom locations. For torsional angles, the distance is the
average of the differences between the torsional angle values, and is independent of atom
locations.
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Each distance value du in the distance matrix represents the similarity between
conformers i and j by comparison of the items in the feature set. The critical distance d*
is incremented from 0 at clustering level 1 (where the number of clusters equals N, the
number of conformers) to the minimum distance du that is more than zero, to create
clustering level 2 with N-1 clusters. As the d* value increases (in accordance with the
increases in the actual du in the intermolecular distance matrix), additional clusters are
formed by combining two clusters found at the previous clustering level. Eventually, all
of the conformers would be in the same cluster; the d* value would reach the highest du
value (representing the two most dissimilar conformers by the feature set criteria) in the
intermolecular distance matrix, and the conformers would become one data set. XCluster
is hierarchical; each cluster is an agglomeration of clusters formed on the previous level,
and no cluster is disassembled at any succeeding level. Figure 2.3 shows an example
data set, along with its distance matrix and the input-ordered and generic-ordered
distance maps. The color-coding of the distance maps is discussed in the next section.
Conformational space coverage and population of clusters can be compared. The
radius of gyration (r g ) of the conformational point cloud is used to measure the
occupation of conformational space. Large values indicate more coverage or "sweep"
through conformational space, and small values indicate less coverage.
Representatives from each cluster can be cluster members, or calculated
conformations that derive from the centroids of the members of each cluster. This study
uses representative conformers that are the members of each cluster that most closely
resembles the calculated "center" (average feature set atom locations) of each cluster, to

Figure 2.3 Example of a simple clustering study. (a) Five conformers, with feature set
of x-y coordinates. (b) Distance matrix. (c) Input-ordered distance map. (d) Genericordered distance map.
ensure that the representative conformer used in the CoMFA and CoMSIA studies is a
local energy minimum.
2.6.2.1 Distance Maps. A first step in the analysis of an XCluster study is review of its
distance map. Distance maps are a color-coded display of the RMSD values for pairs of
molecules in each analog's set of conformers. The distance map therefore summarizes
the many different RMSD values into a small number of RMSD ranges indicated by color
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on a grid. Distance maps for different combinations of feature set/alignment options can
be compared, or distance maps can be evaluated based on their appearance. In this study,
the input order of the conformations was not meaningful, so a generic ordering was used
to display the distance maps. This procedure orders the conformers such that clusters
form from adjoining conformers; multiple generic orderings are possible, depending on
the first conformer selected. The generic ordering displayed in the distance map is not
the only one possible; it is the one generic ordering that starts with conformer 1 of each
analog's data set on the left side.
2.6.2.2 XCluster Basic Statistics. The XCluster run produces simple statistics by
default; there are additional statistics which may be requested when the run is completed.
The seven basic statistics are: 198
•

Clustering level, L : corresponding to N-1-L clusters, where N is the number of
conformers.

•

Critical distance, d*L: the critical threshold distance between the clustering level L
and the previous clustering level, L-1. The critical distances are derived directly from
the distance matrix, and match the exact distance matrix entries. Thus, a sorted list of
all distance matrix values would match a sorted list of critical distances for a
particular clustering study.

•

STe: the reordering entropy. At clustering levels 1 and N, there are N! reorderings.
Each clustering level between 1 and N has a smaller number of reorderings, limited
by forbidden reorderings that break up existing clusters. The reordering entropy is
high when there is a small number of large clusters and low when there is a large
number of small clusters.

•

Number of clusters, k, equals N-1-L, as noted above. This can also be called the
actual number of clusters, to differentiate it from the effective number of clusters.
The actual number of clusters is the sum of all clusters, large and small.

•

Effective number of clusters, k*, corresponds to the "number of large clusters",
calculated as k* = exp (S ep), where:
Set =

x i In x i(2.8)
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and xi = fraction of the data set in the cluster and k = the actual number of clusters at
the clustering level.
• Minimum separation ratio and maximum separation ratio. The separation ratio is the
ratio between the critical threshold distance of the current level, and the critical
threshold distance of the next highest clustering level (the level with one less cluster):

The effective number of clusters is a measure of how many large clusters exist at
a particular clustering level. The effective number of clusters reaches its maximum when
all clusters are of equal size. The maximum effective number of clusters for a given level
is the actual number of clusters, which can be achieved at individual levels, but not
maintained across the entire range of clusters.
For example, if at clustering level N-1, the actual number of clusters equals the
effective number of clusters, which equals two, it can be seen that at clustering level N-2,
the effective number of clusters could not reach its theoretical maximum of three
(because one of the clusters with 50% of the conformers remains, with the other cluster
splitting, at the most evenly distributed, into two clusters containing 25% of the
conformers). This concept is illustrated in Figure 2.4. Qualitatively, the effective
number of clusters measures how many "large clusters" are present at a particular
clustering level for a clustering study, but the more uneven the sizes of the clusters are,
the lower the effective number of clusters. The minimum separation ratio shows how far
apart the most similar clusters are in a set of clusters; this value is important when it rises
above 2, 198 indicating a clear separation between the most similar clusters. The
maximum separation ratio shows how far apart the most dissimilar clusters are in a set of
clusters. These basic statistics are provided as part of the standard XCluster output file.
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Figure 2.4 Diagram of successive clustering levels. Actual (k) versus effective (k*)
number of clusters is demonstrated. Hierarchical clustering prevents splitting of more
than one cluster at a step, thus k = k* cannot be maintained.

2.6.2.3 Cluster Derived Statistics. Although the minimum separation ratio is noted
by Shenkin and McDonald to be a figure of merit,

198

it may not be sufficient to select the

best clustering study or clustering level for all data sets.

198,200,201

Large data sets can have

a continuum of conformations, such that the minimum separation ratio never rises much
above 1. For this reason, the present work defines the novel derived statistic, percentage
change in the effective number of clusters (%DEff), which may be a more useful statistic
for large data sets. The %DEff at level L is calculated as:

where:
%DEff = percentage change in the effective number of clusters
EffL = effective number of clusters at clustering level L
EffL_i = effective number of clusters at clustering level L-1
Act = actual number of clusters at clustering level L

Consecutive application of the distance map and clustering statistics criteria
outlined above leads to determination of the best feature set/alignment option and the
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optimal number of clusters. Identification of the representative conformer for each
cluster is discussed below.
2.6.2.4 Determining Representative Conformers. Once the optimal feature
set/alignment option and clustering level are chosen, the representative conformer for
each cluster is determined as the conformer with feature set atom locations closest to the
average feature set atom locations within the cluster.

2.7 QSAR studies

2.7.1 Review of CoMFA and CoMSIA Methods
This study uses ligand-based QSAR methods because there are no available threedimensional structures of the DAT. 5 The ligand-based QSAR technique CoMFA was
first used to predict the binding of steroid molecules to carrier proteins. 22 Since then,
CoMFA has been used in many applications to determine the relationship between the
structures and electrostatics of a set of compounds and one or more properties of the
compounds. The steric bulk and electrostatic potential fields at various grid points, as
seen by a probe atom, are used to develop a model to predict the biological activity of
each compound. Figure 2.5 shows a representation of the CoMFA procedure, with a
sample grid identified. Each SYBYL CoMFA column shown in the molecular
spreadsheet (i.e., QSAR table) contains a volume estimate of each molecule based on the
number of lattice points contained in the molecule. The columns shown represent the

Figure 2.5 Representation of CoMFA procedure. 22 Three-dimensional grid of points is
shown around a sample compound. Steric and electrostatic potentials are calculated at
each grid point. Partial least squares analysis relates the legend's molecular properties
(S001, ...S998, E001,...E998) to its biological activity ("Biro"), creating a predictive
model. (Reprinted from SYBYL QSAR Manual, Tripos, Inc.)
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thousands of steric or electrostatic potential values that make up the CoMFA field. The
individual values for steric bulk and electrostatic potential fields at grid points are
calculated using Lennard-Jones and Coulombic potentials. Columns are produced in a
SYBYL molecular spreadsheet that represent a specific CoMFA run. Cutoffs are used to
ensure that large values for steric and electrostatic potentials are not weighted too
heavily. The cutoff tells the program that any value above the cutoff is set to the cutoff
value. There is a steric potential cutoff, an electrostatic potential cutoff, and a column
filtering value (o) to even out variations within a CoMFA column.
CoMS1A columns are calculated in a similar manner, with field values calculated
at each grid point; however, Gaussian functions are used to approximate the shape of
each molecule, and properties derived from atom-based descriptors are associated with
the Gaussian functions. 202 CoMS1A is based on the molecular alignment program,
SEAL, 203 which uses rigid bodies to find the maximum overlap of electrostatic and steric
fields. The effect of using the Gaussian function is that the distance-dependence response
of field variables is smoother and singularities possible with Lennard-Jones and
Coulombic potentials used in CoMFA can be avoided. CoMS1A also has the advantage
of a selection of different field types: hydrogen bond donor/hydrogen bond acceptor,
hydrophobic/hydrophilic, and steric/electrostatic.
CoMS1A studies were performed to supplement the CoMFA studies. Since
CoMS1A addresses hydrophobicity and hydrogen donor and acceptors, as well as
electrostatic and steric effects, in addition to the different calculation methods noted
above, the CoMS1A results might provide a different insight into the molecular
requirements of the higher activity 1 analogs. CoMS1A studies can also produce more
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meaningful contour maps because molecular similarity is used to align ligands, allowing
easier identification of areas which can be substituted to improve activity.
Both CoMFA and CoMS1A columns are converted to models through use of PLS.
PLS, also known as projection to latent structures, is used because traditional leastsquares methods cannot be used for the large number of data points created in a CoMFA
or CoMSIA study. The use of the PLS method, developed by Wold et al.,
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allows

manipulation of thousands of x-values, using a modified least squares algorithm to create
a model. An iterative process is used where new variables t o are formed from the x
variables, and used to predict y variables. Each step produces a component, consisting of
a set of to variables known as "scores" or "latent variables". As the number of
components increases, so does the complexity of the model. The limit for the number of
components is one less than the number of objects (molecules) in the study, essentially
modeling the variability in response due to each molecule. Components are therefore
limited to either the SYBYL default of six components, or the rule-of-thumb of one-third
of the number of molecules in the training set (compounds used to form the model).
PLS requires the use of a cross-validation method to determine where the optimal
number of components occurs. Various cross-validation methods exist, all consisting of
leaving out a group of compounds for each run within the cross-validation analysis. The
leave-one-out (LOO) approach has as many groups as molecules; each molecule is left
out once, for a total number of runs equal to the number of compounds in the training set
for each cross-validation run. A correlation coefficients is calculated for the LOO crossvalidation (LOO/CV) run:
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where q 2 equals predictivity and is dimensionless, generally between 0 and 1, but can be
less than zero; PRESS equals predictive residual sums of squares formed from all of the
sums of squares of residuals for each cross-validation run (residual = predicted y-value experimental y-value); and SS(Y) equals sum of the squares of the y variables. The
optimal number of components is identified as the number of components where the q 2
still increases, and the standard error of prediction (based on the residuals found) does not
increase significantly.
The optimal number of components is used for a non-cross-validated (NCV) PLS
study, also known as a "full model" because all molecules in the training set are used to
create it. A second correlation coefficient is created from the NCV PLS analysis, known
as the "goodness-of-fit", r 2 , calculated by:

where r2 equals the goodness of fit and is dimensionless, generally between 0 and 1;
SS(F) equals the sum of the squares of the y residuals, and SS(Y) equals the sum of the
squares of the y variables. Many CoMFA studies show r 2 values in the range of 0.9 or
above, 205 although Wold et al. 204 indicate that q 2 and r2 should be within 0.15 of each
other.
Two standard errors are also calculated; one for LOO/CV PLS analyses
(standard error of prediction, SEP) and the other for NCV PLS analyses (standard error of
estimation, SEE). SYBYL also performs a statistical F-test on the NCV PLS results. The
F value has a general definition of the normalized results of a model divided by one
minus the normalized results of the model. F values for NCV PLS analyses with the
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same optimal number of components can be compared directly, but models with different
numbers of components cannot.
CoMFA and CoMS1A studies using PLS have recently been augmented by the
use of PLS Region Focusing. 206 Region Focusing allows refinement of a CoMFA or
CoMS1A model through increasing the weighting of more important lattice points and
decreasing the weighting of less important points, as indicated by a NCV PLS model.
Use of the PLS method avoids the necessity of x variable selection or x variable
reduction in CoMFA or CoMS1A studies. Although other methods of statistical
treatment of CoMFA x values have been developed, including genetic algorithms, 207 K
nearest neighbor, 208 and neural networks, 209 the application of PLS to CoMFA has
allowed it to become a widely used method.

2.7.2 QSAR Studies on Training Set
Dividing data into a training set and test set allows external validation of a QSAR model.
The QSAR model is based on part of the total data set (the training set), and the
remaining compounds are left out of the model for external validation (the test set). In
the present study, preliminary 3D-QSAR studies were performed on the training set, the
best results focused, and then supported by internal validation using y-value scrambling.
One hundred y-value scramblings using SYBYL's Progressive Scrambling 21 function
were performed on each focused model to estimate their stabilities. This method bins the
activities and scrambles them successively within each bin, thus grouping similar
activities to check the sensitivity of the model to randomness. Ten times the default
number of scramblings were used to minimize the effects of the random seed. Three key
results are produced:
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•

Q 2 = 1 - (sSDEP) 2 : the predictivity of the model, using the scaled standard
deviation of the error of prediction.

•

cSDEP: cross-validated standard deviation of error of prediction

•

dq'2/dryj2: the instantaneous slope calculated where the correlation between the
original data set and the randomized data set is equal to the critical point.
Q 2 is limited by the selected critical point (0.85), and is more conservative than

the cross-validated q 2 calculated in the LOO/CV CoMFA PLS runs. cSDEP can be
compared to the SDEP and the actual error in the experimental samples. Like the q 2 and
SEP results above, Q 2 should be high, preferably above 0.5, but certainly above 0.3, and
cSDEP should be low and similar to SEP. These results were compared to the
recommended cutoffs for stable models, of which the most important is a slope
(dqi2/dryy'2 ) under 1.2. 211

2.7.3 Prediction of Test Set DAT/SERT Selectivities
Experimental and predicted test set DAT/SERT selectivities were used to calculate
correlation coefficients for each of the selected CoMFA models as an external validation
method. 212 The Predicted DAT/SERT selectivity (y) vs. Experimental DAT/SERT
selectivity (x) was plotted to calculate:
•

R2 , the coefficient of determination, of the best-fit line,

•

R, the correlation coefficient, R, of the best-fit line,

•

R0 2 , the coefficient of determination, of the zero-intercept line, and

•

k, the slope of the zero-intercept line.

The reverse relationship, Experimental DAT/SERT selectivity (y) vs. Predicted
DAT/SERT selectivity (x), was also plotted to find:
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•

R'0 2 , the coefficient of determination, of the zero-intercept line of Experimental
vs. Predicted, and

•

k', the slope of the zero-intercept line for Experimental vs. Predicted.
All of the six statistics should be near one, but a model is still considered valid if

either R oe or R' 02 is near 1, and its respective slope, k or k', is near 1. Models that better
predict the test set have all of these statistics near 1. Barring that, the value for R 2 should
be near either the value for R02 or R' 02 . These results were used to compare the predicted
validity of the selected QSAR models.

2.8 Prediction of Novel Compounds
A pharmacophore is a set of required, but not necessarily sufficient, molecular
characteristics that represent a binding (or bioactive) conformation of a set of compounds
at a binding site. The geometry of a molecule determines its conformational elements.
Qualitative pharmacophore mapping was performed using SYBYL's Map CoMFA
function. This feature uses the CoMFA model to highlight areas of the molecules that
would lead to higher activity; areas where varying electrostatic and steric effects by
chemical group substitution leads to more active compounds are identified. This
information was used to predict the DAT/SERT selectivities of novel compounds.
This project resulted in identification of a predictive and stable QSAR model that
was used to identify novel compounds with predicted high DAT/SERT selectivities.
Molecular modeling of synthesized compounds is part of the iterative process of finding
the best compounds to meet the needs of the research. These results will be provided to
the Rice and Rothman groups at N1H as a contribution to ongoing GBR 12909 research.

CHAPTER 3
METHODS

The 3D-QSAR methodology is summarized in Figure 3.1, which reviews the major steps
in a manner applicable to more general QSAR studies. Validation methods can be
applied comparatively or individually, depending upon whether multiple conformations
and/or alignments are chosen for parallel analysis. This project compares six different
QSAR studies which go through the validation steps in parallel; results which do not
meet validation criteria are set aside or reassessed.

3.1 Assumptions
All modeling projects have some level of approximation. In QSAR work, the primary
goal is to develop a model based on the structure and/or conformation of molecules that
yields accurate activity estimates. Assumptions are of three main types: limitations in
scope, accuracy of source data, and software/algorithm approximations.

3.1.1 Limitations in Scope
Thousands of compounds from different classes of DA reuptake inhibitors have been
assessed for activity at the DAT. This project focuses on one subset of the GBR 12909
class of DA reuptake inhibitors, due to Drs. Rice and Rothman's research on the use of 1
and its analogs for agonist substitution therapies for cocaine addiction. Initially, fortyfive compounds based on 1 were selected from over three hundred 1 analogs, and three
compounds, including 1, were added as additional test set compounds. Piperazine and
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An

piperidine compounds were selected based on varying A-side structures, and activities
were reviewed to ensure an acceptable range of activities (more than three log units).

168

Conformational analysis is expected to yield a subset of conformations of all of
the possible low energy conformations of the 1 analogs. This subset is assumed to have
one or more conformations that adequately represent the bioactive conformation of these
compounds in a QSAR model. Detailed conformational analyses were performed only
on 2 and 3; it is assumed that the local minima found for these analogs are significant for
the other 43 analogs. Selection of random search and clustering parameters was done
with this goal in mind. Further approximations are that a static binding conformation can
adequately represent the dynamic changes in a ligand that occur during binding, and that
the bioactive conformation is one of the local minima on the conformational PES of each
molecule.

3.1.2 Accuracy of Source Data
The Venanzi group has access to several different sets of data on DA reuptake inhibitors.
To minimize propagation of errors and allow comparison of data, this research project is
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based on activity data provided by the Rice group from their colleagues in the Rothman
group, both at N1H. The pharmacological tests were performed on the same species of
rat using the same methodology for each type of test. 184 By using binding data from the
same laboratory, the relative accuracy of the calculations is assured.

3.1.3 Software/Algorithm ApproDimations
All calculations were performed on a SG1 Origin 2000 with twenty 300 MHz processors,
20 GB of memory, using the 1R1X ® 6.5.18m UN1X ® -based operating system. Molecular
modeling was carried out with SYBYL Version 6.9 (available from Tripos, Inc., St,
Louis, MO) and Macromodel 8 (available from Schrödinger, Inc., Portland, OR).
Appendix A lists additional software specifications.
A discussion of the basis of the modeling software and algorithms is found in the
Background section of this work. Molecular mechanics methods model atoms and bonds
using macroscopic-scale relationships. Modeling results for molecules not found in the
set of molecules that validated the Tripos force field, such as the 1 analogs, are
approximated from values for individual atom types.
The CoMFA and CoMS1A methods are further approximations, both in the sense
of being based on the Tripos force field, and that the methods both are based on
responses to probe atoms. Default probe atoms were used for all calculations. Grid
spacing and cutoff values for CoMFA further approximate the results. Although studies
have been performed on these factors, no definitive protocols other than use of the default
values have been recommended.
Recording and presentation of CoMFA and CoMS1A results is subject to the
limitations of the modeling software as well. Estimated activities are reported to four or
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more significant figures, yet the expected accuracy of "good" models can be as poor as
one full log unit off or as good as less than 0.1 log unit off from the experimental value.
The CoMFA convention of three digits past the decimal point was used for q 2 , SEP, r2 ,
and SEE.

3.2 Selection of Analogs

A subset of structurally-related compounds was selected from over 300 analogs in the
Rice/Rothman series. The selection criteria included each analog having as few rotatable
bonds and chiral centers as possible, while maintaining either a piperazine or piperidine
ring; having the same 2-[bis-(4-fluorophenyl)methoxy]ethyl- B-side structure; and
pharmacological data covering a wide range of DAT/SERT selectivities. Analog 2 was
selected because it has fewer rotatable bonds than 1 (two on the A-side for 2 versus four
on the A-side for 1), an identical center ring and B-side as compared to 1, but no chiral
centers. An additional 22 piperazine compounds were selected based on 2's scaffold,
differing from 2 only in the A-side substituent. Analog 3 is the piperidine analog of 2,
and 21 additional piperidines were selected, differing from 3 only in the A-side
substituent. DAT and SERT binding affinity and DAT/SERT selectivity are shown in
Table 3.1 for the 45 analogs of 1 in the study. Binding experiments were performed in
the Rothman laboratory using identical protocols. 12,l4,17 DAT binding Kid's range from 0.7
nM for 7 to 100 nM for 12. SERT binding Kid's range from 2.96 nM for 17 to 2090 nM
for 24, with 74% of the compounds with SERT binding K's above 100 nM.
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Figure 3.2 shows the scaffold of the set of analogs of 2 and 3 that were used in
this study. To keep the variations to a minimum, the compounds are either piperazine- or
piperidine-based, have fluorine atoms in the para positions of the B-side phenyl
substituents, and have only one carbon atom between the A-side nitrogen and the A-side
substituent. This QSAR study therefore focuses primarily on the effect of A-side
substitutions. A-side moieties include naphthalene, thiophene, furan, and various phenyl
substituents. There are a few compounds, such as the naphthyl compounds, that have
piperazine and piperidine counterparts. This may be because the piperidine compounds
were developed later than most of the piperazine compounds, so lessons learned from
earlier SAR work on the piperazines were applied. Many of the aromatic substituents are
symmetrical about the A2 torsional angle (e.g. 11, 24, 26, etc.). In cases where the
substituents were not symmetrical, the orientation of the substituent was created to follow
the orientation of the naphthalene substituent in the respective template compound. The
analogs were divided into a test set and training set for 3D-QSAR studies. The test set
was selected to be well-distributed over the range of DAT/SERT selectivities and to be
split between piperazine and piperidine analogs.
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3.3 Conformational Analysis and Clustering
Since it is computationally impractical to carry out conformational analysis of all the
analogs in Table 3.1, 2 and 3 were selected for detailed conformational study. Two
random searches were performed, one on the piperazine 2 and one on the piperidine 3.
Comprehensive hierarchical clustering using XCluster was performed on several hundred
conformations of each analog. A representative conformer in each conformational cluster
was used as a template for building the other 1 analogs by changing the substituents as
necessary, and minimizing each resulting structure. This approximation resulted in a
significant decrease in computational time by not requiring a random search and
clustering study for each of the 48 compounds.

3.3.1 State of Protonation
Studies on DA binding have shown that it most likely binds to the DAT in the protonated
state. 213 Cocaine is thought to exist as a 90/10 mixture of protonation states, favoring the
protonated form, but having similar conformations in the neutral and protonated forms. 27
HF/6-31 G* molecular orbital calculations performed on 1 showed that protonation of the
A-side nitrogen is favored over the B-side nitrogen. 214 This agrees with binding studies
of piperidine analogs of 1 that show that the binding affinity for the DAT is substantially
higher when the A-side nitrogen rather than the B-side nitrogen is present. 172 The A-side
nitrogens in 2 and 3 were therefore modeled with an associated proton.

Figure 3.3 Diagram of 3 and its features. Identified are potential pharmacophore
elements, key torsional angles and key atoms.

3.3.2 Random Search Conformational Analysis
Two random search conformational analyses were performed on the minimized structures
of 2 and 3 by Milind Misra and Deepangi Pandit from the Venanzi group, using the eight
torsional angles (Al, A2, B1, B2, B3, B4, B5, and B6) noted in Figure 3.3. Each search
was performed for 10,000 cycles over an energy range of 20 kcal/mol from the GEM;
additional parameters are found in Appendix A — Software Specifications and Input
Parameters. SYBYL Version 6.9 with the Tripos force field was used to calculate
conformations and energies. The detailed protocol for the random search conformational
analysis of 2 has been published elsewhere. 215 The same protocol was repeated for 3. A
full analysis of the conformational profiles of 2 and 3 will be given in a future
publication. 61 The conformers were converted from SYBYL mol2 to Macromodel mae
multiple molecule file format for analysis by XCluster.
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3.3.3 Clustering
Hierarchical clustering using XCluster 198 (Schrodinger, L.L.C., Portland, OR) was
performed to determine representative conformers of 2 and 3 from the large data sets
produced by the random searches. Various feature sets were examined and the resulting
clustering statistics and distance maps were analyzed to determine the most appropriate
clustering feature set and clustering level. A representative conformer was selected from
each of the major clusters found at the selected clustering levels. These representative
conformers were then used as templates from which the other analogs in Table 3.1 were
constructed, creating conformational families. The clustering techniques used are
summarized in three flowcharts, found in Figures 3.4, 3.5, and 3.6, and described below.
3.3.3.1 Initial Clustering Studies. Clustering studies were performed on the sets of
conformers produced by random search as noted above. The multiple feature
set/alignment options explored are shown in Table 3.2 and their use is described in Figure
3.4. Distance matrices were constructed separately for analogs 2 and 3 based on these
options. Each entry in the distance matrix consists of the RMSD of the atoms or torsional
angles in the feature set calculated for pairs of conformers superimposed according to the
chosen alignment option. Table 3.2 shows the combinations of atoms or torsional angles
used in the clustering studies and the superpositions where applicable. Atoms and angles
used in the feature set/alignment options are identified in Figure 3.3. The feature sets
range from all heavy atoms (options a and b) to key atoms that contain the DAT
pharmacophore elements (quaternary nitrogen and aromatic ring on the A-side) (options
c — e) to key atoms that contain the bisphenyl substituent required for 1 analog binding

(options f — j). These are coupled with alignment options which superimpose the
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molecules by the center ring atoms or all heavy atoms (options a, b, c, and)) or focus on
the A-side DAT pharmacophore elements (options d and e) or on the B-side atoms
(options g — j). XCluster216 was used to calculate intermolecular atomic or torsional
RMSD values. Symmetry options were set to the default, which handles basic symmetry
issues, such as symmetry of some aromatic groups around torsional angle A2.
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3.3.3.2 Selection of the Optimal Number of Clusters. Two levels of review were
necessary to select the optimal number of clusters. First, the distance maps for each
feature set/alignment option were reviewed for both analogs, and those that showed small
numbers of well-defined large clusters were selected for further analysis, as shown in
Figure 3.5. Review of distance maps focused on the number of large squares present on
the diagonal, and the relationship between these squares. For the goal of finding a
manageable number of clusters in order to identify representative conformations for a
future CoMFA study, maps with 10 or fewer large squares on the diagonal (with few or
no small squares) were deemed to be most appropriate. In other words, the best distance
maps would show relatively few large boxes centered on the black diagonal line that
represents each conformer being compared to itself. This type of distance map identified
the feature/set alignment option that was selected for detailed analysis (calculation of
clustering statistics). Maps with many small squares along the diagonal, indicating many
small clusters, were not analyzed further. For individual clustering studies, this initiated
the selection of a new set of features and rerunning XCluster (see Figure 3.5).
In the second phase, the percentage of conformers included in the large clusters
was calculated and the maps which had the largest percentages were selected for
calculation of clustering statistics (minimum separation ratio, actual and effective number
of clusters, percentage change in the effective number of clusters). These statistics were
used to determine the optimal clustering level and associated optimal number of clusters,
as shown in Figures 3.5 and 3.6. For example, clustering statistics were calculated for the
20 highest clustering levels for each selected feature set/alignment option. If the
minimum separation ration was above two for a particular clustering level compared to
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neighboring levels with values around one, that level was identified as the optimal level,
as shown in Figure 3.5. If all the clustering levels had about the same minimum
separation ratio (around one), then the percentage change in the effective number of
clusters, along with a comparison of the effective versus actual number of clusters, was
used to identify the optimal clustering level and the optimal number of large clusters, as
shown in Figure 3.6. In addition, the radius of gyration was calculated to determine the
coverage of conformational space by the selected clusters.

3.3.4 Representative Conformers
Once the optimal feature set/alignment option and clustering level were chosen, the
representative conformer for each cluster was determined as the conformer with feature
set atom locations closest to the average feature set atom locations within the cluster.
The representative conformers of analogs 2 and 3 in each cluster were compared by
calculating the RMSD values for the fit of the feature set atoms as well as all heavy
atoms. This was accomplished by converting each conformer of 3 into a pseudo 2
structure by replacing the carbon atom with a nitrogen and removing the "extra"
hydrogen. This allowed Database RMSD Fit calculations using SYBYL, which can only
be done on a database of identical molecules. A visual comparison of the pairs of closest
related analog 2 and 3 representative conformers was also made, using superimposed
structures.
Templates for the conformational families to be used in the QSAR studies were
selected by determining which conformers of the piperazine and piperidine 1 analogs had
the lowest RMSD among pairs of conformers. Conformational families were numbered
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by succeeding feature set values (in this study, by ascending A1 and A2 torsional angle
values) of their template conformers.

3.4 Creation of Conformational Families
Each piperazine (or piperidine) representative conformer was used as a template from
which to build the remaining 22 (or 21) analogs shown in Table 3.1. Each of the
conformational families identified had one template for piperazine 1 analogs, and another
template for piperidine 1 analogs. These templates were used as a basis for creation of
the sets of 1 analogs to use in the CoMFA and CoMSIA studies. A SYBYL
Programming Language (SPL) script was used to modify each pair of template structures
to create the other analogs. SYBYL's Log Session command was used to record the
creation of a set of 1 analogs. The recorded commands were saved as a SPL file and
modified to make a script that created the other forty-three 1 analogs from the 2 and 3
templates. A sample script is given in Appendix B. The sets of 1 analogs were placed in
separate databases, one for each cluster. The script was also used to reset the torsional
angles A1 and A2 to the values found in the cluster's template, minimize each structure,
and fit the atoms to align the analogs.
Twenty-two additional piperazines were created based on each 2 template, and
twenty-one additional piperidines were created based on each 3 template. For each
analog, the A-side naphthalene moiety was removed, and replaced with the appropriate
new substituent from Table 3.1. In cases where the aromatic substituents were not
symmetrical, the orientation of the substituent was made to match that of the 2-naphthyl
substituent in the respective template compound. Thus, the second ring in fused ring
substituents would overlap that of the naphthalene substituent in 2 or 3 as much as
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possible. The new substituent was added with the average A1 and A2 torsional angle
values for the piperazine 2 and piperidine 3. Each molecule was minimized for 1,000
iterations using the Tripos force field l63 with Gasteiger-Htickel charges. 2I7 The
additional test set compounds (all piperazines) were constructed individually from analog
2, minimized, and aligned in the same manner as the other compounds.

3.5 Molecular Alignment
Each analog in the series was aligned to analog 24 (R = H), the analog with the smallest
substituent, using the four atoms comprising the A1 torsional angle. An atom-based
alignment had been used in the Venanzi group's previous methyiphenidate study and
other28 studies of the DAT's cocaine binding site. This alignment is based on the atoms
that are proposed to be included in the DAT cocaine binding site pharmacophore.
Alignments reviewed included all heavy atoms and the five atoms comprising the A1 and
A2 torsional angles. The selected alignment is based on the four atoms in the torsional
angle Al. This aligns the key part of the nitrogen-based pharmacophore. Carbon atom
25, the final atom in torsional angle A2, could not be included because the smallest 1
analog has only a methyl substituent and no atom 25, and therefore could not be aligned
on the A1 and A2 atoms.
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3.6 CoMFA and CoMSIA Studies
3.6.1 CoMFA and CoMSIA Study-Specific Concerns
Many published articles on CoMFA 22 use SYBYL's default settings. Work by the
Venanzi group has indicated that improved models can be found by varying the CoMFA
parameters." Although the column filtering value (a) was also changed, the most
significant effect was in response to changing the electrostatic and steric energy cutoffs
from the default settings of 30 kcal/mol each. The research conducted on modifying
electrostatic and steric energy cutoffs used a grid of electrostatic cutoffs from 10 to 60
kcal/mol and steric cutoffs from 10 to 250 kcal/mol. The CoMFA studies were
performed at nine different sets of electrostatic and steric cutoffs to decrease the
computation time but still cover a range of settings.

3.6.2 CoMFA and CoMSIA Preliminary and Focused Studies
Preliminary QSAR studies were performed on each of the six conformational families,
consisting of 45 analogs apiece. The procedure followed for the QSAR studies is
outlined in Figure 3.1. A molecular spreadsheet was created from the SYBYL molecular
database of each conformational family of analogs. Energies and activities were added as
columns, with DAT binding affinity and SERT binding affinity being entered directly
and the DAT/SERT selectivity being calculated from the two binding affinities. CoMFA
and CoMSIA columns were added to the molecular spreadsheet.
CoMFA runs were performed using electrostatic values of 10, 30, and 50
kcal/mol, in conjunction with steric cutoffs of 10, 30, and 50 kcal/mol, for a total of nine
steric/electrostatic cutoff parameter combinations, the 30 kcal/mol steric and 30 kcal/mol

55

electrostatic combination being the SYBYL default setting. CoMSIA runs were
performed for hydrogen bond donor/acceptor, hydrophobic, and steric/electrostatic fields.
Default settings were used for the remaining CoMFA or CoMSIA parameters in each run.
After the columns were added, the six rows for the test set compounds were "hidden" in
the molecular spreadsheet to perform QSAR on the remaining 39 training set compounds.
Sample-distance Partial Least Squares (SAMPLS) 218 was used to calculate q 2 values for
the preliminary QSAR studies. LOO/CV calculations were carried out for each of the
twelve studies (nine CoMFA and three CoMSIA) for each family. For each family, the
most predictive model was identified as that with the highest value of q 2 . The parameter
combination (CoMFA) or field choice (CoMSIA) and optimal number of components of
the most predictive model were used to calculate a NCV PLS model for each family in
this preliminary series of calculations.
To refine the models, Region Focusing was performed on the most predictive
model for each family identified through the preliminary studies above using the
parameter combination for CoMFA or field choice for CoMSIA that gave the most
predictive NCV PLS model. The SYBYL default Region Focusing parameters were
used. The focused CoMFA or CoMSIA column was analyzed with both a = 0 and a = 2
kcal/mol cutoffs, after initial SAMPLS screening, to ensure the highest q 2 values were
obtained.
The q 2 (predictivity), standard error of prediction (SEP), r2 (goodness-of-fit), and
standard error of estimate (SEE) results of the focused models were compared, and the
results validated using two different methods. Activities of the training set compounds
were predicted using the optimal number of components from the NCV PLS region-
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focused models. The CoMFA and CoMSIA results were analyzed, and the models
derived were subjected to training set (internal) validation and test set (external)
validation methods. After CoMFA and CoMSIA columns were added to the molecular
spreadsheets, PLS analyses were performed to determine the best models. LOO/CV
SAMPLS 218 calculations were run on the DAT/SERT selectivity/QSAR column
combinations. For each cluster, the highest q 2 was selected for further analysis.
LOO/CV full calculations with the default a (column filtering value) of 2 kcal/mol was
used to calculate q 2 again. The full NCV PLS calculation was carried out with the default
of no a applied (a=0 kcal/mol, column filtering off). The q 2 values, standard errors of
estimate, r 2 values, and standard errors of predictions were recorded. The best molecular
field combination was then rerun using SYBYL's Focus CoMFA function, which can be
applied to any field type. LOO/CV PLS and NCV PLS calculations were performed for
the focused model, and the model statistics recorded. The models with the highest q 2 and
lowest standard error of prediction were selected as the most predictive models. Both the
initial best models and focused models were used to determine the overall best models of
the cluster set. Models with q 2 values above 0.5 were checked for stability to random
noise.

3.7 Interpretation of Modeling Results
To avoid depending on q 2 and r2 values alone for identification of a predictive model, 212
the compounds selected were divided into a training set and a test set to determine the
accuracy of predicting the activities of known compounds. The test set consisted of six
compounds selected to span the range of activities and the two types of 1 analogs
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included in this study. In addition, y-value scrambling210'211 (in this study, the y-values
are the DAT/SERT selectivities) was used to estimate the stability (the effect of
randomization of the y-values, or the resistance to "noise") of the best models using the
training set.
The selected region-focused QSAR model for each family was then used to
predict the test set DAT/SERT selectivities. The test set compounds were displayed and
the Predict Activity command used to find the DAT/SERT selectivity of each compound.
The predicted DAT/SERT selectivities for each region-focused model were used to
calculate residuals and to validate the model using test set correlation validation.

3.8 Prediction of Novel Compounds
SYBYL's Map CoMFA function was used to produce a three-dimensional steric and
electrostatic contour map. The map was analyzed to determine where the greatest impact
of changing steric or electrostatic characteristics of a 1 analog would be. Interpretation,
in terms of locating important areas, was based on the template molecules 2 and 3. The
SYBYL Optimize QSAR procedure was used to replace hydrogen atoms in key locations
identified on the CoMFA contour map with different substituents, and predict the
DAT/SERT selectivities of the new molecules.

CHAPTER 4
RESULTS

4.1 Random Search Conformational Analysis
Seven hundred and twenty-eight conformations were found for the piperazine 2, and 739
conformations were found for the piperidine 3. These conformations were used as the
input data to the clustering studies. Figure 4.1 shows the conformer sets for 2 and 3. The
large number of conformers required use of clustering to identify a small number of
representative conformers from the larger data sets.

4.2 Clustering of Conformers
Clustering was carried out using the Macromodel module XCluster. The optimal number
of clusters was selected by application of the distance map and clustering statistics
criteria described in the Methods section.

4.2.1 Clustering Distance Maps
Distance maps created from the 10 clustering feature set/alignment combinations are
shown in Figures 4.2 and 4.3. Small RMSDs, representing high similarity, are shown by
the color black (where the RMSD = 0) or blue. The colors graduate through green,
yellow, orange and finally red for the highest RMSDs, representing the least similar
conformations. The scale varies based on the RMSD range of the study; blue might
represent a range from 0 to 0.5 A in one clustering study, and 0 to 2
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A in another

Figure 4.1 Random search results for 1 analogs. (a) The piperazine 2 and (b) the
piperidine 3. Conformers are superimposed on center piperazine (2) or piperidine (3)
ring.

Figure 4.2 Distance maps for analog 2 clustering studies. Black borders on left and
bottom sides represent generic-ordered conformers. Distance maps are color-coded by
interconformational distances, from black through blue to red. Blue boxes along the
diagonal represent clusters of conformers; large boxes contain many conformers, and
small boxes contain only a few conformers. Distance maps are lettered by the feature
set/alignment options identified in Table 3.2.

Figure 4.2 Distance maps for analog 2 clustering studies. Black borders on left and
bottom sides represent generic-ordered conformers. Distance maps are color-coded by
interconformational distances, from black through blue to red. Blue boxes along the
diagonal represent clusters of conformers; large boxes contain many conformers, and
small boxes contain only a few conformers. Distance maps are lettered by the feature
set/alignment options identified in Table 3.2. (Continued)

clustering study. The distance maps were reviewed to select those with a small number
of large clusters for further analysis. The results of the review of the distance maps are
shown in Figure 4.4.
4.2.1.1 All Heavy Atoms Feature Sets. The all heavy atom feature set distance maps

are shown in Figures 4.2(a), 4.2(b), 4.3(a), and 4.3(b) and correspond to feature
set/alignment options a and b, as noted previously in Table 3.2. All four distance maps

Figure 4.3 Distance maps for analog 3 clustering studies. Black borders on left and
bottom sides represent generic-ordered conformers. Distance maps are color-coded by
interconformational distances, from black through blue to red. Blue boxes along the
diagonal represent clusters of conformers; large boxes contain many conformers, and
small boxes contain only a few conformers. Distance maps are lettered by the feature
set/alignment options identified in Table 3.2.

Figure 4.3 Distance maps for analog 3 clustering studies. Black borders on left and
bottom sides represent generic-ordered conformers. Distance maps are color-coded by
interconformational distances, from black through blue to red. Blue boxes along the
diagonal represent clusters of conformers; large boxes contain many conformers, and
small boxes contain only a few conformers. Distance maps are lettered by the feature
set/alignment options identified in Table 3.2. (Continued)
show numerous small squares on the diagonal, indicating that major clusters were not
found. The large amount of small squares on the diagonal is indicative of the diversity of
the conformations when the analogs are viewed as a whole. These maps and their
associated clustering studies were not analyzed further. Instead, attention was focused on
clusters defined by A-side and B-side feature set/alignment options.
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4.2.1.2 A-Side Feature Sets. The distance maps for the A-side analyses are shown in
Figures 4.2(c), 4.2(d), 4.2(e) and 4.3(c), 4.3(d), 4.3(e), and correspond to feature
set/alignment options c, d, and e in Table 3.2. Five of the six distance maps show
relatively well-defined major clusters on the diagonal, and therefore require further
analysis to select the most promising feature set/alignment option. Only the distance map
in Figure 4.3(c) shows many small clusters on the diagonal, as well as off-diagonal blue
areas representing similarity between large clusters, and was not used for further analysis.
Comparison of the other two A-side feature set distance maps (options d and e) for both
analogs shows a strikingly similar clustering pattern for the A-side clustering analyses.
The distance maps selected for analogs 2 (Figures 4.2(c), 4.2(d), and 4.2(e)) and 3
(Figures 4.3(d) and 4.3(e)) show six large clusters on the diagonal. For each map, the
clustering level which gave an effective number of clusters closest to six was selected to
calculate the percentage of conformers in each major cluster. These results are reported
in Table 4.1. The table shows that for analog 2 feature set/alignment options c and e and
analog 3 feature set/alignment option d, more than 99% of the conformers are included in
the six major clusters. For analog 2 feature set/alignment option d and analog 3 feature
set/alignment option e, these values are 95% and 97%, respectively. The A-side
clustering studies result in evenly-populated clusters; the smallest of the major clusters
for each feature set/alignment option contains 10% or more of the conformers in each
data set. The largest minor clusters (selected from the clusters not included in the six
major clusters) contain one-third or fewer conformers compared to the smallest major
clusters.
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Plots of the effective number of clusters, k*, versus the actual number of clusters,
k, for the selected feature set/alignment options are given in Figures 4.5 (analog 2) and
4.6 (analog 3) for the 20 highest clustering levels. The straight line where k = k* is also
plotted for comparison. Again, the results are similar for each of the five feature
set/aligmnent options, although it is interesting to note where the large jumps in the
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effective number of clusters occur. Options 2(c), 2(e) and 3(d) are the only clustering
studies that separate into six effective large clusters (k* = 6) in the 10 highest clustering
levels, with the effective number of clusters closer to the actual number of clusters than
the other two A-side studies listed in the table.
These analyses led to the identification of options 2(c), 2(e) and 3(d) as the most
promising clustering studies for analogs 2 and 3. However, because the goal is to use the
clustering studies to select representative conformers of 2 and 3, which are included in
the same QSAR studies, selection of the same clustering feature set/alignment option is
preferred. As noted above, option 3(c) does not cluster well according to its distance
map, so option c was not selected. Options 2(e) and 3(e) were selected for further
analysis because the percentage of conformers in the six major clusters in option 2(e) is
slightly better than that in option 3(d). Similarly, the percentage of conformers in the
major clusters for option 3(e) is better than option 2(d) (3.0% not covered versus 4.7%
not covered, respectively). Option e was used to confirm the optimal number of clusters
for A-side clustering, as detailed in the section Review of Clustering Statistics.
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4.2.1.3 B-Side Feature Sets. The distance maps for the B-side analyses are shown in
Figures 4.2(f) — 4.2(j) and 4.3(f) — 4.3(j), and correspond to feature set/alignment options
f —j in Table 3.2. For both analogs, options f and j result in many small clusters along the

diagonal. Distance maps in Figures 4.2(f), 4.2(g) and 4.2(j) show many small clusters on
the diagonal, and wide distribution of blue and green points, indicating distances between
separate clusters are about the same as distances within clusters. Distance map 4.2(i)
shows well-defined squares on the diagonal, but there are 15 or more squares present, not
meeting the criteria of 10 or fewer major clusters. For analog 2, only the distance map in
Figure 4.2(h) shows less than 10 large clusters on the diagonal and was selected for
further analysis. For analog 3, Figures 4.3(h) and 4.3(i) show large clusters on the
diagonal, although those in Figure 4.3(h) are less clearly defined. The distance maps for
options f, g, and j for analog 3 show many small clusters on the diagonal.
The B-side distance maps show different sizes of large clusters along the diagonal
as compared to the A-side distance maps. Nine large clusters can be qualitatively
identified when looking for trends in the three distance maps shown in Figures 4.2(h),
4.3(h), and 4.3(i).
In contrast to the A-side distance maps that were comparable for analogs 2 and 3,
the B-side clustering studies for 2 and 3 do not match well for several feature
set/alignment options. Of note is the comparison of Figure 4.2(i) and 4.3(i), where a
distinctly different pattern is seen. Comparison of this same clustering option for the two
analogs indicates that analog 2 may be able to access many more different types of B-side
conformations than analog 3.

The selected analog 2 (Figure 4.2(h)) and 3 (Figures 4.3(h) and 4.3(i)) distance
maps all show approximately nine large clusters on the diagonal. The percentage of
conformers left out of the nine major clusters is shown for the three B-side clusterings in
Table 4.2 and indicates that the major clusters represent less of the entire data set than
those of the selected A-side analyses. The selected B-side analysis option 2(h) has a
wider distribution of cluster sizes, as indicated by the lowest effective number of clusters
(5.88) compared to the number of major clusters (nine) and by the small size of the
smallest major cluster (1.1% of total set of conformations). Both of these attributes are
due to a significant size range of the major clusters as seen in Figure 4.2(h). The B-side
clustering studies produced a mixture of differently-sized major clusters for both 2 and 3,
although the analog 2 studies produced more variation in B-side cluster size. The
smallest of the major clusters for each feature set/alignment option contains 3% or less of
the conformers in each data set. The largest minor clusters (clusters not included in the
nine major clusters) are not of significant size and follow a trend similar to the A-side
studies.
The B-side effective number of clusters versus the actual number of clusters is
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the three clustering studies. It can be seen that option 3(g) has a minimal increase in
effective number of clusters as the actual number of clusters increases, indicating
splintering as opposed to formation of large clusters. The patterns for the other B-side
clustering studies (option h for both analogs) are similar, and are not revealing in terms of
where to determine the optimal number of major clusters. Although the review of the
distance maps led to an estimate of nine major clusters, Figures 4.7 and 4.8 show that
nine major clusters do not occur until k, the actual number of clusters, is more than 20.
Based on these results, further analysis was not performed on the B-side clustering
studies; only clustering option e, using A-side features, was selected for analysis of
additional clustering statistics for each analog.
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Figure 4.7 B-side effective vs. actual number of clusters for analog 2. Feature

set/alignment option 2(h) and theoretical maximum. Clustering level is noted on top xaxis for reference. Open triangle - Option 2(h). Solid line - Theoretical maximum (k =
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4.2.2 Review of Clustering Statistics
An analysis of the minimum separation ratio and the percentage change in the effective
number of clusters based on Figures 3.5 and 3.6 was used to confirm the optimal number
of clusters for options 2(e) and 3(e). Table 4.3 lists the 20 highest clustering levels in
descending order, and their associated data: minimum separation ratio, critical distance,
actual and effective number of clusters, and %AEff for the clustering levels of option
2(e). The highest minimum separation ratio is 1.23. Table 4.4 lists the same set of data
for the 20 highest clustering levels of option 3(e). The analog 3 data shows an even
smaller range of minimum separation ratio for high clustering levels, the highest value
being 1.17. Both values of minimum separation ratio fall significantly below the
recommended value of 2.0 197 for identification of the optimal clustering level. Therefore,
it appears that the minimum separation ratio is not a useful criterion for these clustering
studies.
The %AEff values were compared for the 20 highest clustering levels as well.
This value is a numerical representation of the trends seen in Figures 4.5 (analog 2) and
4.6 (analog 3), scaled by the number of actual clusters at the clustering level, as noted in
equation 2.10. The %AEff is large for clustering levels where a large jump in the
effective number of clusters occurs, as long as the actual number of clusters is low.
Following the procedure for selecting the optimal clustering level in Figure 3.6,
review of Table 4.3 identified clustering level 719 (approximately six effective clusters,
10 actual clusters, 13% change, minimum separation ratio 1.12) for option 2(e).
Similarly, review of Table 4.4 identified clustering level 729 (approximately six effective
clusters, 11 actual clusters, 11% change, minimum separation ratio 1.06) for option 3(e).
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4.2.3 Visualization of Clusters and Representative Conformers
Clustering levels representing six major clusters were chosen based on the selected Aside analyses (both option e, A1/A2 torsional angle feature set). For the purposes of the
proposed QSAR work, the agreement of the A-side results for both analogs and the small
number of similarly-sized A-side clusters led to a focus on the A-side for more detailed
analysis. The representative conformers for each cluster were used to develop
conformational families of analogs.
Two views of the conformers of 2 in the six major clusters at clustering level 719
of option e are shown in Figure 4.9. Structures in the figure are superimposed on the
piperazine ring, with only the A-sides shown. The relative orientation of the naphthalene
ring in the conformers is defined by torsional angles A1 and A2. The physical
significance of torsional angles A1 and A2 is that they determine how the conformers
form natural groups on the A-side of the molecule. The A1 torsional angle describes
rotation about a N(sp 3 )-C(sp 3 ) bond and the A2 torsional angle describes rotation about a
C(sp 3 )-C(sp 2 ) bond. Therefore, the A1 and A2 torsional angles of the conformers output
by the random search technique should be close to the values of torsional angles found in
the staggered low-energy conformations of compounds such as aminomethane and
methylbenzene, which can be considered to be models for the A1 and A2 torsional angle
rotational barriers, respectively. Figures 4.9(a) and 4.9(b) show that the six clusters form
regularly around the A1 torsional angle, resulting in three pairs of clusters. The six
clusters correspond to conformational energy minima for rotation around the A1 and A2
torsional angles. These patterns can be seen in Figure 4.10 which shows the potential
energy surface in (Al, A2) space with conformers color-coded by cluster. The figure
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shows the clusters are located about 120° apart on the A1 axis (at approximately -60°,
+60°, and ±180°. The location of these clusters corresponds to rotational minima around
the N(sp 3 )-C(sp 3 ) bond in Al, and is typical of the rotational energy minima in
aminomethane. The figure also shows that most of the conformers are found clustered
along the A2 axis at approximately A2 = -90° and +90°, while the remaining conformers
are spread along the axis at intermediate values of A2. The location of the clusters
corresponds to rotational minima around the C(sp 3 )-C(sp 2 ) bond in A2. This complex
pattern of rotational minima is due to the effect of the large substituent groups on the
carbons in the C(sp 3 )-C(sp 2 ) bond in A2. Similar results were obtained for option 3(e).
Figure 4.11 shows the six pairs of representative conformers (representing six
family templates) found in the clustering study that span the three-dimensional space
occupied by analogs 2 and 3. The attributes of the 12 representative conformers, six each
for 2 and 3, from the cluster studies with feature set/alignment option e are shown in
Table 4.5. Clusters in Table 4.5 were ordered by increasing A1 and A2 values of the
representative conformers, on a scale of -180° to +180°. The energy of each conformer is
given relative to the global energy minimum (GEM) structure for each analog. The table
shows that the A-sides of the representative conformers for the six clusters are very
similar for the two analogs. The table also shows little difference between the relative
energies of the representative conformers for analog 2 (7.54 to 9.50 kcal/mol) and analog
3 (3.53 to 5.45 kcal/mol). Neither analog has its GEM as a representative conformer.
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(b)

(a)

Figure 4.9 Two views of six major A-side clusters for analog 2. Clusters are colorcoded as per Table 4.5. Center ring and B-side are not shown for clarity. (a) Front view.
(b) Side view.
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Figure 4.10 Cluster membership A1/A2 plot of the 728 conformers of analog 2.
Conformers are color-coded by their cluster, as noted in Table 4.5, with conformers not
in a major cluster colored black.
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Figure 4.11 Two views of analog 2 and analog 3 representative conformers.

Representative conformers are color-coded by their cluster, as noted in Table 4.5. Center
ring and B-side are not shown for clarity. (a) Front view. (b) Side view.
Table 4.5 Representative Conformers for Analogs 2 and 3 a

Cluster
1
1
2
2
3
3
4
4
5
5
6
6

Analog_
Conformer
Numberb
2_256
3_578
2 _453
3_653
2 593
3 246
2_546
3_258
2_101
3 _489
2_573
3 _254

A1
(degrees)
-179.2
-174.6
-176.2
-171.3
-60.7
-59.7
-62.5
-63.5
60.1
65.2
57.9
62.5

A2
(degrees)
-133.0
-114.7
72.4
50.2
-55.6
-64.8
114.8
122.8
-96.0
-90.0
84.6
85.5

Real.
Energy
(kcal/mol)
9.50
3.76
8.16
5.11
8.19
3.53
9.50
5.10
7.54
5.45
8.34
4.04

Cluster
Color in
Figures d
red
red
magenta
magenta
blue
blue
cyan
cyan
green
green
yellow
yellow

Feature set/alignment option e.
Conformer number in random search output.
Relative energy is given compared to the global energy minimum of the entire set of conformers for
each analog.
d Color of cluster, in Figure 4.9; cluster member, in Figure 4.10; and representative conformer pair, in
Figure 4.11.
a

b
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For each cluster, the feature set torsional angles A1 and A2 are similar for analogs
2 and 3. These two angles control the relationship between the nitrogen atom in the
center ring and the aromatic moiety (in these analogs, naphthalene) on the A-side, key
characteristics of the majority of DA reuptake inhibitors. The template conformers can
be broken down into three groups of two conformers each, based on their A1 values.
Each group has A1 values offset by approximately 120°, indicating that they are truly
representative of the three pairs of clusters shown in Figure 4.9. In each cluster, the A1
values are within 5° for each pair of representative conformers.
Analysis of the A2 values shows a difference of approximately 180° between the
pairs of clusters with similar A1 values (clusters 1 and 2; clusters 3 and 4; clusters 5 and
6), having differences of A2 ranging from 165° to 205°. This indicates "flipping" of the
naphthalene ring, by rotation around the C(sp 3 )-C(sp 2 ) bond in A2, by approximately
180°. This degree of variability from a perfect flip is attributed to the fact that the
adjacent N(sp 3 )-C(sp 3 ) bond of the A1 torsional angle has only one large substituent,
allowing a range of A2 angles around the C(sp 3 )-C(sp 2 ) bond.
The six representative conformers for the A-side clustering option 2(e) were
reviewed to determine the diversity of their B-side structures. The B-side option 2(h),
noted above as most suitable for further analysis, was used to determine the population of
nine major clusters, and the locations of each of the six A-side representative conformers
were identified. Three of the six representative conformers were found in one B-side
cluster, and the other three were found in three different clusters. The three A-side
representative conformers that were found in the same B-side cluster are clusters 1, 3, and
5, which all have negative A2 torsional angles.
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4.2.4 Comparison of the RMSD of Representative Conformer Pairs
Figure 4.12 shows the 12 representative conformers for the selected clustering levels of
the A-side option e superimposed on the center rings. Table 4.6 lists the clusters and the
RMSD between the conformers of analogs 2 and 3 in each of the six major A-side
clusters. The first RMSD column was calculated based on the same atoms used for
feature set/alignment option e. The second RMSD column was calculated based on
superposition of all heavy atoms in the molecules. The first RMSD values indicate that
the five heavy atoms defining A1 and A2 have very similar locations in space for the
representative conformer pairs. This can be seen in Figure 4.11. The increase in the
RMSD for all heavy atoms is due to differences in the B-side atoms.

4.2.5 Comparison of the Conformational Space Coverage
Tables 4.7 and 4.8 show the radii of gyration of the conformational point cloud for each
data set, along with the six major clusters selected. The minor clusters are included for
comparison; their results are shown in italics. Torsional angle A1 and A2 values are only
reported for the six major clusters.
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(a)

(b)

(c)

(d)

(e)

(0

Six pairs of representative conformers from clustering study.
Figure 4.12
Representative conformers for Cluster 1 (a) through Cluster 6 (f). Each pair contains a
conformer of 2 and a conformer of 3.
Table 4.6 Comparison of Representative Conformers of
Analogs 2 and 3
RMSD of Atoms in
RMSD of All
Feature Set/Alignment
Heavy Atoms (A)
Cluster
Option e (A)
0.22
2.37
1
2.24
0.31
2
1.77
0.12
3
1.95
4
0.10
2.00
0.13
5
1.79
0.08
6
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The radii of gyration for all conformers are nearly identical (less than 3%
difference) for each analog, indicating that the piperazine and piperidine analogs cover a
similar amount of conformational space. The amount of coverage for each cluster is not
directly related to the number of conformers in each cluster. For example, analog 2
Cluster 3 has 82 conformers and reaches 33.7
conformers and reaches only 20.2

A, whereas analog 2 Cluster 4 has 151

A. This equates to almost twice as many conformers

in Cluster 4 covering two-thirds of the conformational space covered by Cluster 3.
In addition to the absolute conformational space coverage, the relative
conformational space coverage determined by review of the distance maps and related
data is of interest. The A-side distance maps show clusters of approximately the same
size, as viewed in the distance maps and by the effective number of clusters being near
six when the number of major clusters is six.

4.3 Construction of Conformational Families
The representative conformers in Table 4.5 were used as templates to construct
conformational families of analogs. For example, Family 1 consists of 2, in conformation
256 (of the 2 random search results) and the other 22 piperazines in a minimized
conformation that was derived from conformation 256, as well as 3, in conformation
number 578 (of the 3 random search results) and the other 20 piperidines in a minimized
conformation that was derived from conformation 578. Members of each conformational
family other than 2 and 3 themselves were minimized from the template conformations to
avoid singularities and reach their local energy minima. Conformational families are
therefore distinguished from clusters as being developed from the representative
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conformer of each cluster; clusters contain only conformations of 2 or 3, and the
conformational families each contain all 45 analogs in the 3D-QSAR study.

4.4 QSAR Studies
Six analogs were selected as a test set, three piperazines (5, 8, and 13), and three
piperidines (29, 32, and 35), the remaining 39 analogs forming the training set. The
substituents varied; three substituted phenyl substituents, a benzothiophenyl substituent, a
cyclopentanonyl substituent, and a quinolinyl substituent. These substituents are similar
to those of the analogs in the training set. Figure 4.13 shows the 45 analogs, including
both the training set and test set, created from the templates for Families 1 through 6.

4.4.1 QSAR on Training Set
The results of the preliminary set of QSAR studies are summarized in Table 4.9. Under
"Best Results" for the LOO/CV models, the table reports the pair of steric and
electrostatic cutoffs (of the nine combinations tested for each family) that gave the
highest q 2 . For comparison purposes, the "CoMFA Default" column shows that generally
similar, but lower in all cases, values of q 2 were obtained by using SYBYL's
steric/electrostatic default values of 30/30. The default results for Family 4 were most
different from the highest q2 results, with the CoMS1A steric/electrostatic field option
yielding a q 2 value 0.078 higher than the q 2 value for the CoMFA 30/30 setting.
Although all the "best" and "default" models found in the preliminary QSAR studies have
values of q 2 below the generally-accepted criterion of 0.5 for a predictive CoMFA or
CoMS1A mode1, 219 all are above the statistical 95% confidence limit of q2 = 0.3.220 SEP
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a)

b)

c)

d)

e)

f)

Figure 4.13 Conformational families, showing alignment of all analogs. (a) Family 1.
(b) Family 2. (c) Family 3. (d) Family 4. (e) Family 5. (f) Family 6.
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(55.5% electrostatic contribution versus 44.5% steric contribution). The hydrophobic
field, which gave the best model for Family 2, does not provide a similar
steric/electrostatic distribution.
The results of refining the best preliminary model for each family by Region
Focusing are given in Table 4.10. For most conformational families, setting the column
filtering (a) value to 2 kcal/mol gave similar values of q 2 compared to the SAMPLS
results (6=0), with almost no difference (0.002) for Family 2 and 0.113 difference for
Family 3, the filtered result having a lower q 2 value. Compared to the preliminary NCV
PLS models of Table 4.9, all families (except Family 2) show a decrease in the steric
contribution and increase in the electrostatic contribution. Family 1 has the largest
decrease, 22%. Families 5 and 6 show 16% and 14% decreases in the steric
contributions, respectively. All SAMPLS q 2 values increase in the focused models, with
substantial increases seen for Families 1, 5 and 6. These three families meet the criteria of
2
q 2 values more than 0.5. Acceptable r2 values are seen for most families; however, the r

values for the Family 1 and Family 6 two-component models are just below 0.7. The r 2
values are approximately the same for the focused versus the preliminary models for all
families. However, the r 2 values for the six-component models of Family 1 and Family 6
are significantly higher than those for the two-component models identified in the
preliminary studies (two models are listed for Family 1 and Family 6 due to the
instability of the six-component models as detailed below).
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The stabilities of the QSAR models were estimated using SYBYL's Progressive
Scrambling y-value scrambling procedure. Table 4.11 shows the results of 100 y-value
scramblings on the eight different QSAR models listed in Table 4.10. The scrambling
results for the six-component Family 1 and Family 6 models are poor because the values
of dq 2 Vdryy2 are greater than 1.2. 210 The maximum number of components was reduced
to five (instead of the default six) and the QSAR studies were rerun. The LOO/CV
SAMPLS runs for both families indicated that two components are optimal at this
setting. The two-component Family 1 and Family 6 CoMFA models have q 2 values of
0.511 and 0.508, respectively (Table 4.10), and both have dq 2 Vdryy'2 values indicating
stability.
Q 2 values were lower than the q 2 values in all cases, ranging from -1.454 to 0.405,
but these are known to be more conservative than LOO/CV PLS q 2 values.21 The results
for Family 4 indicate a significant amount of instability. Calculated cross-validated
standard deviation of error of prediction (cSDEP) values were similar to SEP values for
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all but the six-component Family 1 model and the Family 4 model. Once again these
values are lower than their LOO/CV counterparts. These results indicate that four of the
eight listed models are expected to be stable and acceptably resistant to perturbation by
random noise. The dual criteria of q 2 of 0.5 (or above) and stability to random noise were
used to select three of these models (the two-component models for Families 1, 5, and 6)
for detailed review, the fourth stable model (Family 2) having a q 2 value less than 0.5.
Training set DAT/SERT selectivities from the stable focused NCV PLS model
results for Families 1, 5 and 6 are shown in Figure 4.14. The r 2 values of approximately
0.7 appear as deviations of data points from the ideal diagonal line in all three plots.
Average residuals for the training sets are 0.00 for all three models; the averages of the
absolute value of the errors are 0.35, 0.33, and 0.34 for the Family 1, 5, and 6 models,
respectively. A list of the training set predictions for these models is included in
Appendix C. Analog 21, the cyclohexenophenyl piperazine analog, was predicted the
poorest by Family 1 (residual = -1.13), and analog 20 was also predicted poorly (residual
= 1.06). Analog 20 was predicted the poorest by both Family 5 and Family 6, with
similar residuals (1.10 and 1.20, respectively). Both analogs 20 and 21 have fused rings,
with a nonaromatic ring proximal to the A-side nitrogen, and an aromatic ring distal to
the A-side nitrogen. Predictions for the similar piperazine analogs 16, 17, 18, 19, and 22,
and the similar piperidine analogs 43 and 44, were reviewed to determine if these
compounds were predicted poorly as well. The range of experimental DAT/SERT
selectivities for the seven piperazines is -0.87 to 1.61, or 2.48 log units. Analogs 19
(residuals = -0.76, -0.69, and -0.75, for Families 1, 5, and 6, respectively) and 22
(residuals = 0.11, 0.83, 1.02, for Families 1, 5, and 6, respectively) are also predicted
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poorly for most families. However, analogs 16 and 18 are predicted well (residuals =
-0.27, -0.45; -0.24, 0.08; and 0.40, and 0.11, for Families 1, 5, and 6, respectively),
although one is a ketone and the other is an alcohol. Analog 17, which is the same as
analog 16 with a distal methoxy group, is predicted somewhat poorly (residuals = 0.61,
0.37, and 0.61, for Families 1, 5, and 6, respectively). The piperidine analog 43 is
predicted somewhat poorly (residuals = 0.94, 0.45, and 0.56, for Families 1, 5, and 6,
respectively), but its stereoisomer analog 44 is predicted well for two families (residuals
= 0.56, 0.20, and 0.14, for Families 1, 5, and 6, respectively). Overall, these three
CoMFA models appear to predict the nonaromatic/aromatic fused ring analogs relatively
poorly. The trend of piperazines being more poorly predicted than the piperidines seems
to be due to the higher percentage of these nonaromatic/aromatic fused ring substituents
in the piperazine analog set.
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Figure 4.14 GBR 12909 analog QSAR study - training set predictions. (a) Family 1,
two components. (b) Family 5, two components, (c) Family 6, two components.
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4.4.2 Prediction of Test Set DAT/SERT Selectivities

The three selected QSAR models were used to predict the DAT/SERT selectivities of six
test set compounds (the piperazines 5, 8, and 13, and the piperidines 29, 32, and 35).
Table 4.12 lists the predicted DAT/SERT selectivities and the associated residuals for
these test set compounds. The average residuals are 0.31 for Family 1, 0.32 for Family 5,
and 0.25 for Family 6. These numbers are noticeably higher than the average residuals
found for the training set. However, the piperazine 8 is a significant outlier for all three
families, predicted to have a much higher DAT/SERT selectivity than the experimental
DAT/SERT selectivity for all three models. When this single compound is removed,
reducing the test set from six to five compounds, for Family 1, the average residual drops
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to 0.07; for Family 5, the average residual is reduced to 0.00; and for Family 6, the
residual become -0.02. The reduction in error of prediction is less noticeable when
considering the absolute values of the errors, with Family l's average decreasing from
0.61 to 0.41; Family 5's average decreasing from 0.69 to 0.46; and Family 6's average
decreasing from 0.63 to 0.45. Except for the one outlier, the piperazines were underpredicted by all three models. Two of the piperidines, analogs 32 and 35, were predicted
well for all three families. The third piperidine, analog 29, was predicted poorly possibly
because it is the only 2-substituted phenyl analog in the series, and is therefore somewhat
dissimilar from the training set.
Interestingly, analog 8 was mentioned in a previous paper on 1 analogs because
its experimental DAT/SERT selectivity (-0.04) was inconsistent with the DAT/SERT
selectivities of similar compounds.'' Analogs 9 and 10, also piperazines, have quinolinyl
A-side substituents with different connectivities. Experimental results show 9 has a
better than average DAT/SERT selectivity (1.48) and 10 a somewhat lower but
acceptable value (0.95). The DAT/SERT selectivity of 9, the 3-quinolinyl analog, was
predicted well, with residuals of 0.12, 0.15, and 0.09 for Families 1, 5, and 6,
respectively. Analog 10's DAT/SERT selectivity had higher residuals of 0.66 for Family
1, 0.77 for Family 5 and 0.71 for Family 6.
The test set predictions were also used to validate the models, according the
methods outlined by Golbraikh and Tropsha. 212 The outlying data for 8 was removed
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from the original test set for these calculations, since its residual is much larger than the
residuals for the other compounds. Table 4.13 includes the test set correlation validation
results for the reduced original test set of five compounds, and Figure 4.15 shows the
plots of the predicted DAT/SERT selectivities versus the experimental DAT/SERT
selectivities for the reduced original test set of five compounds.

96

97

The reduced original test set coefficient of determination values for the best-fit
lines (R2 ) are similar. The R 2 values for the reduced original test set predictions are less
than half the goodness-of-fit found for the training set (r 2 ), chiefly because of large
residuals for analog 29. The Golbraikh and Tropsha paper recommends having a test set
of at least five compounds, so an extended test set of seven compounds was developed
using three additional compounds (1, 47, and 48), leaving out analog 29 as an additional
outlier. The structures and the predicted DAT/SERT selectivities for these three
additional compounds, which are more flexible (have more rotatable bonds on the Aside) than the other compounds in the QSAR study, are shown in Table 4.14. The test set
validation
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correlation values for the extended test set (n=7), listed in Table 4.13 and plotted in
Figure 4.16, are higher than those for the reduced original test set (n=5). All three
coefficients of determination for the Family 6 model are above 0.7 (0.746, 0.735, and
0.722), slightly more than the goodness-of-fit (r 2 ) for prediction of the training set
compounds (0.685). The improved correlation of the extended test set results compared
to the reduced original test set results can also be seen by comparing Figures 4.15 and
4.16. Details of the test set predictions are found in Appendix D. This method of
CoMFA model validation indicates that the Family 6 model can predict test set
compounds satisfactorily, although the presence of two outliers among nine candidates
for the test set raises questions about the general applicability of the Family 6 model.
The results of this study show that models with acceptable q 2 values of 0.5 or above do
not necessarily predict activities well for all related compounds.

4.4.3 Prediction of Novel Compounds
Figure 4.17 shows the CoMFA steric/electrostatic contour maps for Family 6, with
analog 3 shown as a reference molecule. Green areas indicate where an increase in bulk
would lead to a higher DAT/SERT selectivity; yellow areas indicate where a decrease in
bulk would lead to a higher DAT/SERT selectivity. Blue areas indicate where an
increase in positive charge would lead to a higher DAT/SERT selectivity; red areas
indicate where an increase in negative charge would lead to a higher DAT/SERT
selectivity.
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Figure 4.17 CoMFA steric/electrostatic contour map for Family 6 model.
There are several key features of the CoMFA contour map that are predicted to
increase DAT/SERT selectivity:
•

Less bulk near positions 3 and 4 of the 2-naphthyl substituent

•

More bulk near positions 5, 6, and 7 of the naphthyl substituent

•

A more positive environment above the naphthyl plane, away from the center
ring, extending axially from position 3

•

A more negative environment near position 6

Of most interest is the area near positions 5, 6, and 7, where more bulk is predicted to
increase DAT/SERT selectivity. However, the multiple small areas where less bulk leads
to a higher DAT/SERT selectivity restrict opportunities for increasing DAT/SERT
selectivity by adding bulky substituents. The red areas near positions 6 and 7 correspond
to a para substituent on a phenyl analog of 3, which is supported by the high DAT/SERT
selectivities of analogs 30 and 36.
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The scaffold used for the novel compounds was the phenyl piperidine analog 26,
since the phenyl-substituted compounds 30 and 36 are the most active compounds in the
QSAR series. An exhaustive search of replacing the position 3 and position 4 phenyl
hydrogens (corresponding to positions 5, 6, and 7 of the 2-naphthyl analog) of analog 26
with one of 17 substituents similar to those found in the QSAR training set compounds
was run and the DAT/SERT selectivities of the compounds (without minimization) were
predicted. The complete list of substituents is included in Appendix E. Table 4.15 shows
nine compounds that have predicted DAT/SERT selectivities higher than the most active
analog, 36 (DAT/SERT selectivity of 2.70), for the Optimize QSAR run that did not
perform minimization of each structure. The predicted DAT/SERT selectivities found in
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additional runs, where minimization was performed, used only the two most active
position 4 substituents and substituted each of the 17 groups at position 3.
Both the -CF 3 and -CN groups impart some bulk and negative electrostatics to
position 4 of the phenyl ring. In addition, both position 4 substituents, -OCN and
-CH2CN are moderate electron withdrawing groups, causing the phenyl ring to be more
positive. The -NH2 group and -OH group are both strong electron donating groups,
which lead to an increase in electron density at the ortho and para positions, and a
decrease in electron density (a positive environment) near the N and 0 atoms of the
substituents. Therefore, five of the substitutions at position 3 may address the blue area
identified on the CoMFA contour map where a more positive environment is expected to
yield a higher activity. Although these compounds do not show significant predicted
DAT/SERT selectivity increases, their high activities indicate the potential for
exploration of 3,4-disubstituted phenyls.

CHAPTER 5
DISCUSSION

5.1 Comparison of Piperazine and Piperidine Clustering Results
The results of the clustering study indicate that there is no major difference in the rotation
of the A-side substituent when comparing the piperazine analog 2 to its piperidine
counterpart 3. Minor differences in the orientation of the A-side exist when comparing 2
and 3. The results of the B-side analysis show less agreement between the two analogs;
the presence of the methyne substituent instead of the nitrogen appears to lead to a wider
distribution of cluster sizes. However, this could be an artefact of the calculation due to
incomplete searching of conformational space or characteristics of the Tripos force field.
These results show that when independent clustering studies are performed on
these piperazine and piperidine analogs of 1, the results are strikingly similar for the Aside analysis. This clustering study found consistent results for the A-side of the
piperazine analog, 2, and the piperidine analog, 3. The highly flexible B-side was more
difficult to analyze, and may require additional analysis to accurately represent the
possible conformations. The size of the clusters seen in the B-side clusterings varies to a
greater extent, which may indicate that the random search did not fully populate each
cluster or the smaller clusters represent a smaller range of low-energy conformers.
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5.2 CoMFA and CoMSIA Studies

5.2.1 Using Multiple Fields and Field Settings for QSAR Development
A range of electrostatic and steric cutoffs for CoMFA columns and different CoMSIA
columns were used in this study. A review of Table 4.9 shows that for this data set and
alignment method, the q 2 values found for the best settings were from 0.020 to 0.078
higher than those found for the default CoMFA setting of 30 kcal/mol for steric and
electrostatic cutoffs. The Venanzi group's previous work on methylphenidate showed
from 0 to 30% increase in q 2 values between CoMFA runs at the default steric and
electrostatic cutoffs of 30 kcal/mol each, with average q 2 increases of approximately 10%
predictivity of data; however, a larger range of steric and electrostatic cutoffs was used."
The amount of time to perform eight extra CoMFA calculations, and three CoMSIA
calculations is minimal compared to the time to perform conformational analysis and
alignment, so it is believed that routinely including these extra field columns and
requisite PLS runs may be worth the time spent.
In this study, CoMSIA fields gave the best q 2 values for two of the six families,
Family 2 and Family 4. These two families had the third and fourth highest q 2 values of
the six families in the preliminary QSAR studies. After focusing the models, Family 4
(static/electrostatic field CoMSIA model) had only a small increase in q 2 after focusing,
making it by far the lowest q 2 value of the six (eight with the reduced models included)
focused models. Family 2 (hydrophobic field CoMSIA model) dropped from third to
fourth when ranking q 2 values. Increase in q 2 values for the CoMSIA families was found
to be minimal (+0.020) for Family 4, and low (+0.107) for Family2. This contrasts the
other four families; the four CoMFA models were improved to a greater extent by
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focusing (+0.189/0.188, +0.120, + 0.128, +0.140/0.120 for Families 1, 3, 5, and 6,
respectively). It is unclear whether this small improvement when applying Region
Focusing to CoMS1A models is somehow related to CoMS1A models themselves, or an
artefact of these particular models. Larger studies of CoMS1A models would be
necessary to determine if this is a general effect.

5.2.2 Use of Same Template for Piperazine and Piperidine Analogs.
Separate random searches were performed on the piperazine 2 and the piperidine 3.
QSAR studies using analog 2 as the only template (building the piperidine analogs of 1
by substituting a methyne substituent for the B-side nitrogen) were initially tested
because the representative conformers clustered well for both analogs 2 and 3.
Predictivities were poor, therefore the present study was done using both 2 and 3 as
templates. This brought the different B-side conformations as an alignment issue; most
of the B-sides for the 2 templates did not match their 3 counterparts' B-sides. It is noted
that the CoMFA map (Figure 4.17) has no areas of interest near the B-side. It was found
that the positions for the B-sides appeared not to vary enough between each pair of
templates to affect the CoMFA contour map significantly.

5.2.3 "Near-minimization" and Minimization
The Venanzi group's previous methyiphenidate CoMFA study used a methylphenidate
template with atom or group substitution for phenyl hydrogens, and no minimization for
single atom substituent." This method allows perfect alignment, which may be
expected for single and few atom substituents. This series of 1 analogs is more diverse
than the methyiphenidate analogs, therefore minimization of each analog after changing a
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substituent is much more important. Casual molecular modelers are cautioned to ensure
complete minimization of their molecules; for a molecule of this size, the iterations were
increased from the default of 100 iterations to 1,000 iterations. Any molecule that still
had a high energy (more than 10 kcal/mol from other analogs in the series) was further
checked by applying extra minimization steps manually to confirm the final value. In
this study, 1,000 iterations were sufficient for proper minimization of each analog.
Proper minimization of substituents was supported by the use of SYBYL library
fragments for the A-side substituents.
For screening of novel potentially active compounds using Optimize QSAR, the
initial exhaustive runs were performed on unminimized structures. The best results of
this preliminary exhaustive run were used to develop a smaller Optimize QSAR run that
only had two possible substituents in position 4, since these two substituents appeared in
every compound predicted to be more active than analog 36. The second run allowed the
full set of the original 17 substituents for position 3, and the structures were minimized
before activities were predicted. This combination of unminimized and minimized
structures is an efficient way to target the most likely beneficial substituents, without the
significant time effort of an exhaustive and fully minimized structure run.

5.2.4 Inclusion of Racemic Compounds in the QSAR Studies

Forty-three of the forty-eight compounds studied either have no chiral centers or were
isolated as a specific stereoisomer. The inclusion of five compounds synthesized as
racemic mixtures in this 3D-QSAR study was based on the data available at the time of
the research. All five compounds (13, 14, 15, 16, and 17) are published in one paper, 20°
and are cyclic ketones with one chiral center; three are single ring and two have two
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fused rings. These compounds were modeled with the chirality that best aligned with the
naphthyl substituent in analog 2, with the ketone group extending into the same area
covered by the naphthol substituent. Research into the use of racemic compounds in
QSAR studies from the Journal of Medicinal Chemistry indicates that multiple QSAR
studies based on data from racemic mixtures have been published in the first eight issues
of 2005. For example, Budriesi et al.'s paper on selective myocardial calcium channel
modulators 221 uses racemic data for all but one of their compounds, and makes chirality
assumptions for both one and two chiral center compounds; this data is used as an input
for a 3D-QSAR study. Other QSAR studies, such as Gallardo-Godoy et al.'s work,

222

do

not explicitly mention racemic mixtures, but the structures of certain compounds (e.g., 29
and 30 in the referenced paper) implicitly indicate chiral centers.
A QSAR study on Family 6 performed with a training set of 35 compounds,
excluding the four racemic compounds in the present study's training set (one racemic
compound, 13, being in the present study's test set), resulted in decreased q 2 values for all
CoMFA and CoMS1A parameter/field combinations. The results are listed in Appendix
F. The results of the present QSAR studies with and without the five racemic compounds
indicates that the data based on racemic mixtures provides valuable information for this
QSAR series. Colleagues at the NUT are presently working on expanding the GBR
12909 series of compounds, including additional stereoisomerically pure compounds.
5.2.5 LOO/CV with Column Filtering versus SAMPLS

Screening was performed using the SAMPLS method. 218 This method consistently gives
the same results as a PLS run with a, the column filtering cutoff value, set to zero.
However, a "full" PLS run using a a equal to 2 kcal/mol has been in the past
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recommended to calculate q 2 , to expedite calculations and to remove values that may not
be as predictive as values that vary more widely. In this study, there were sometimes
differences between the a = 0 (SAMPLS) and a = 2 results, from 0 to 11% explanation of
activities in either direction. Performing SAMPLS calculations is expeditious for
multiple studies, allowing performance of many field and parameter settings in a short
amount of time. Performing at least both SAMPLS and a = 2 cross-validated PLS runs
for the best models from preliminary studies would be recommended to find the best a
setting for a particular data set and methodology, although discussions with Tripos
personnel indicate that column filtering is becoming obsolete. Here the SAMPLS results
are presented for the Preliminary CoMFA results, and both the a = 0 and a = 2 kcal/mol
results for the Focused CoMFA runs because the models' q 2 values varied depending on
the a setting. For consistency, the SAMPLS results were used to determine the optimal
number of components for the NCV runs.

CHAPTER 6
CONCLUSIONS

This work illustrates a QSAR study of a highly flexible family of drug-like molecules.
Representative low-energy conformers were gleaned from large sets of random search
conformers using hierarchical clustering. QSAR runs were performed on six
conformational families, which were developed by modifying representative low-energy
conformers of two template molecules. The process of developing a QSAR becomes
parallel; considering different steric and electrostatic cutoffs for CoMFA and different
fields for CoMSIA yields models of varying predictivity. Comparison of the q 2 values
after focusing the QSAR models is a first way to determine potentially acceptable
models. An acceptable q 2 must be backed up by internal validation, such as y-value
scrambling,210,211 and external validation, such as test set correlation validation, 212 to
further ensure the validity and applicability of high-q 2 models. Validity of the QSAR
model can be supported by predicting the activities of novel compounds. The results of
this work will be provided to Drs. Rice and Rothman at the NUT to support their ongoing
SAR work on the GBR 12909 family of analogs. Future collaborations are planned to
continue 3D-QSAR model and pharmacophore development.
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APPENDIX A
SOFTWARE SPECIFICATIONS AND INPUT PARAMETERS

This appendix contains the software specifications and parameter settings for the
SYBYL ® molecular modeling program used to complete the QSAR studies of GBR
12909 analogs.

Software:

SYBYL/Base Version 6.9.1

Manufacturer: Tripos, Inc., St. Louis, Missouri, USA
Platform:

SGI Irix 6.5

SYBYL CoMFA Parameters:
All settings left as default (below), except for changes in electrostatic and steric cutoffs.
CoMFA Field Class: Tripos Standard
Field Values: Type(s): Both
Dielectric: Distance
Smoothing: None
Drop Electrostatics: Within Steric Cutoff for Each Row
Transition: Smooth
Region: Create Automatically

SYBYL CoMSIA Parameters:
All settings left as default (below), except for changes in selected field.
CoMSIA Field Parameters: Attenuation Factor: 0.3
Region: Create Automatically
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SYBYL PLS Parameters:

PLS: For all runs:
Scaling: CoMFA Standard
For cross-validated (leave-one-out) runs:

"Leave-One-Out" box checked
"Use SAMPLS" box: checked for Leave-One-Out SAMPLS runs
(Maximum Number of) Components:

6*

* Except when number of components needed to be limited in response to poor stability
of higher component model.
For full PLS runs:

"No Validation" box checked
Components: (as found in best cross-validated run)

APPENDIX B
SYBYL PROGRAMMING LANGUAGE SCRIPT EXAMPLE

In this appendix, a portion of a SPL script is included as an example of the scripts used to
create and minimize the GBR 12909 analogs.

buildA111.spl
# Build base structures - one for C.3 atoms and one for C.ar atoms.
# First, load in Analog 2 template for conformational family.
MOL MULT IN M1
/afs/cad.njitedu/researchichem/venanzi/4/Project/analog_creation/new_reps.mdb/c11REP
pDM324_00256.mol2
ORIENT BEST VIEW M1
# Remove the centroids, and the naphthalene aggregate (for future minimization
simplification).
REMOVE CENTROID (*) *
REMOVE AGGREGATE NAPHTHALENE AGGREGATE
# Add it to the conformational family database.
DATABASE OPEN
/afs/cad.njit.eduiresearch/chem/venanzi/4/Project/QSARII/lpALL.mdb UPDATE
MODIFY MOLECULE NAME M1 "lpDM-DM324-2-naphthylTEMPLATE"
DATABASE ADD "Ml"
# Remove some atoms, and save as Carbase (C.ar base structure)
REMOVE ATOM
M1((((((((((((((33)+66)+32)+31)+65)+30)+64)+29)+63)+62)+28)+27)+26)+61)
112
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MODIFY MOLECULE NAME M1 "lpDM-Carbase"
# Put in conformational family database, will delete at end.
DATABASE ADD "Ml"
# Change atoms 24 and 25 to C.3 atoms, then rename and put in database.
MODIFY ATOM TYPE M1((25)+24) C.3 C.3
MODIFY MOLECULE NAME M1 "1pDM-C3base"
DATABASE ADD "Ml"
# Make C.3 C.2 base.
MODIFY ATOM TYPE M1(25) C.2
MODIFY MOLECULE NAME M1 "1pDM-C32base"
DATABASE ADD "Ml"
ZAP M1
# PART II - Create 22 analogs from the base structures for the conformational family,
either using
# a database of side groups or directly using atom modification and adding hydrogens.
##### Build DM-325 (l-naphthyl)
# Put C.ar base for conformational family in M1 area, works for first set of Analog 2
analogs. This will be repeated as analogs are built.
DATABASE GET "lpDM-Carbase" M1

# Open database of A-side groups. Because it is last opened, it becomes default.
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DATABASE OPEN
/afs/cad.njit.edu/research/chem/venanzi/4/Project/analog_creation/DMAsides.mdb
UPDATE

# Get the A-side group from the DMAsides database.
DATABASE GET "naphthalene" M2
FUSE M1(23) M2(14) M1(24) M2(4) M1(25) M 2 ( 10 )1
# Put it in conformational family database by switching it to the default database.
DATABASE DEFAULT
/afs/cad.njit.edu/research/chem/venanzi/4/Project/QSAR_II/lpALL.mdb
MOD1FY MOLECULE NAME Ml "lpDM-DM325-1-naphthyl"
DATABASE ADD "M1"
# Get rid of molecules.
ZAP M1
ZAP M2

(program continues in a similar manner for each analog)

APPENDIX C
CoMFA AND CoMSIA STUDY RESULTS

Detailed CoMFA and CoMS1A preliminary study results are contained herein.
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APPENDIX D
PREDICTIONS FOR TEST SET COMPOUNDS

The SYBYL output for the predictions of all of the test set compounds are contained in
this appendix.
D.1

Original Test Set Predictions
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Ignored 52 of 3009 terms (missing data, used column mean)

AAAAAAA

Predicting 6PTP-TP1134-2-METHOXYPHENYL ( M4 )
Row 46 6PTP-TP1134-2-METHOXYPHENYLX Column #13 (FOCUSS3OE1O) :
COMFA
... prediction of LSDR for 6PTP-TP1134-2-METHOXYPHENYLX : 1.57328
AAAAAAA

Extrapolated 212 of 3009 terms (data outside range); sum is 7.01147e-05

AAAAAAA

Ignored 49 of 3009 terms (missing data, used column mean)

Predicting 6PTP-TP227-4-TOLYL ( M5 )
Row 46 6PTP-TP227-4-TOLYLX Column #13 (FOCUSS3OE1O) : COMFA
... prediction of LSDR for 6PTP-TP227-4-TOLYLX : 1.73129
AAAAAAA

Extrapolated 5 of 3009 terms (data outside range); sum is -0.0447089

AAAAAAA

Ignored 46 of 3009 terms (missing data, used column mean)

Predicting 6PTP-TP231-4-CHLOROPHENYL ( M6 )
Row 46 6PTP-TP231-4-CHLOROPHENYLX Column #13 (FOCUSS3OE1O) :
COMFA
... prediction of LSDR for 6PTP-TP231-4-CHLOROPHENYLX : 2.04843
AAAAAAA

Ignored 46 of 3009 terms (missing data, used column mean)
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APPENDIX E
LIST OF SUBSTITUENTS FOR NOVEL COMPOUNDS

This appendix contains a table showing the 16 sub stituents, excluding the default of a
hydrogen atom, that were used in the Optimize QSAR studies to predict novel
compounds.
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APPENDIX F
CoMFA AND CoMSIA STUDY RESULTS FOR FAMILY 6 WITH
NON-RACEMIC TRAINING SET

This appendix contains the results of a QSAR study on Family 6 using a reduced training
set created by removing the four racemic compounds (14, 15, 16, and 17) from the
training set that was used in the bulk of the study.
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